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ABSTRACT 
THERAPEUTIC EFFICACY OF P53 RESTORATION IN MDM2-
OVEREXPRESSING TUMORS 
 
 
Qin Li 
 
Advisor: Guillermina Lozano, Ph.D. 
 
The TP53 tumor suppressor is the most mutated gene in human cancers. 
Recent studies using genetically modified mouse models have shown that 
restoring the expression of wild-type p53 has led to tumor growth suppression in 
various types of tumors lacking p53. Other mechanisms, e.g. upregulation of 
Mdm2 levels, exist in tumors to inactivate the p53 pathway. Mdm2, an E3 
ubiquitin-ligase that targets p53 for proteasomal degradation, is present at high 
levels in many tumors with wild-type p53. In this study, we probed the effects of 
restoring p53 activity in Mdm2-overexpressing tumors genetically using animal 
models. Here we demonstrated high levels of Mdm2 and low levels of p53 act 
additively to dampen p53 activity in DNA damage response and tumor 
development, suggesting a dose-dependent tumor-suppressive function of p53.  
Our data also indicate that restoration of wild-type p53 expression in 
spontaneous Mdm2-overexpressing angiosarcomas resulted in tumor stasis and 
regression in some cases. We further showed that the restored p53 suppressed 
vii 
cell proliferation in the Mdm2-overexpressing angiosarcomas but did not elicit 
apoptosis. Therefore, we conclude that restoration of wild-type p53 expression in 
tumors with high levels of Mdm2 represents a potential strategy to treat these 
tumors. This finding is of important clinic relevance since a large number of 
human tumors have high levels of Mdm2. Our present work suggests that p53 
restoration confers therapeutic potentials even to tumors with high levels of 
Mdm2. 
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CHAPTER 1. INTRODUCTION 
The Basics of Tumor Suppressor p53 
p53 is the most frequently altered gene in human cancers (Cheok et al., 
2011). In 1979, the p53 protein with a molecular weight of approximate 53 kDa 
was independently discovered in different studies via virologic and serologic 
approaches, respectively. In simian virus 40 (SV40) transformed cells, p53 was 
co-immunoprecipitated with SV40 large-T antigen, suggesting that p53 and large-
T antigen exist in the same complex (Chang et al., 1979; Kress et al., 1979; Lane 
and Crawford, 1979; Linzer and Levine, 1979; Melero et al., 1979). Yet, p53 
protein was also immunoprecipitated from the murine Meth A sarcoma cells or 
transformed mouse cells by mouse antisera against Meth A cells (DeLeo et al., 
1979). Moreover, p53 expression was detected in all transformed mouse cells 
but not in non-transformed mouse cells (DeLeo et al., 1979). Although the nature 
and function of p53 was far from clear at that time, these early observations 
collectively suggested a correlation of p53 with cellular transformation.  
It was therefore of interest to decipher the role of p53 in transforming events. 
Using a variety of approaches, several laboratories demonstrated that p53 
expression positively correlated with induction of cell proliferation (Calabretta et 
al., 1986; Mercer et al., 1984; Mercer et al., 1982; Milner and McCormick, 1980; 
Reich and Levine, 1984).  In addition, inhibition of p53 by a variety of means led 
to suppression of cell proliferation in both transformed and non-transformed cells 
(Mercer et al., 1984; Mercer et al., 1982; Shohat et al., 1987). Ectopic expression 
of p53 not only immortalized normal cell lines (Jenkins et al., 1985; Jenkins et al., 
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1984), but also cooperated with expression of other well-known oncogenes e.g. 
H-Ras to transform these cells (Eliyahu et al., 1984; Jenkins et al., 1984; Parada 
et al., 1984). All of these data suggested an oncogenic nature of p53 until it was 
finally revealed that the “wild-type” p53 used in these aforementioned 
transformation studies was indeed mutated. 
In search for potential tumor suppressor genes on chromosome 17p, which 
were found deleted in more than 75% of colorectal carcinomas, a small region 
containing p53 gene was identified (Baker et al., 1989). Further analysis of gene 
status at the p53 locus revealed its compliance with the Knudson’s Two-hits 
theory of tumor suppressor genes during oncogenesis (Knudson, 1971):  one 
copy of p53 gene was completely deleted while the other one was often altered 
by point mutations in these colorectal tumors (Baker et al., 1989). Later, similar 
p53 gene alterations were observed in a variety of tumor types (Nigro et al., 
1989). These unexpected findings suggested p53’s role as a tumor suppressor 
and not as an oncogene, which was supported by additional observations that 
exogenous expression of wild-type p53 suppressed cell proliferation and 
oncogene-medicated transformation (Eliyahu et al., 1989; Finlay et al., 1989). 
The tumor suppressor role of p53 was further confirmed by the studies of Li-
Fraumeni syndrome. These patients carry germline mutations of p53 and are 
susceptible to an early onset of various types of tumors (Malkin et al., 1990; 
Srivastava et al., 1990). In order to examine the causal role of p53 loss during 
tumorigenesis, several research groups independently generated genetically 
engineered p53-null mice, in which both p53 alleles were deleted (Donehower et 
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al., 1992; Jacks et al., 1994; Lowe et al., 1993). These mice, although born 
normal, developed tumors at early ages with 100% penetrance, sealing the tumor 
suppressive role of the p53 protein.  
 
The Structure of the p53 Protein 
Due to its important role in tumorigenesis, extensive efforts have been 
dedicated to resolve the structure of the p53 protein. The analysis of p53 
structure was possible with cloning of both human and mouse p53 cDNAs (Bienz 
et al., 1984; Zakut-Houri et al., 1985). Although the protein encoded by human 
cDNA with 393 amino acids is longer than that of mice by 2 amino acids, these 
two p53 proteins share a great deal of identity and homology at the primary 
sequence level (Zakut-Houri et al., 1985). To date, 5 functional domains have 
been identified within the p53 protein (Figure 1), which are from the N-terminus to 
the C-terminus, the transcription activation domain (TAD), the proline-rich domain 
(PRD), the central DNA binding domain (DBD), the tetramerization (TET) 
domain, and the C-terminus regulatory (CT) domain (Joerger and Fersht, 2008). 
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Figure 1. Functional domains of the p53 protein. The p53 protein contains five 
functional domains: a negatively charged transactivation domain (TAD), a 
proline-rich domain (PRD), a DNA binding domain (DBD) that binds a specific 
DNA sequence, a tetramerization domain (TET), and a C-terminus regulatory 
domain (CT).  Numbers at the bottom indicate the beginning and ending amino 
acids of each domain.  
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The TAD, which remains unfolded, provides binding sites for various types of 
factors including the basic transcription machinery components, the 
transcriptional coactivators, and the negative regulators of p53 (Joerger and 
Fersht, 2008). One of the most important factors that binds the TAD of p53 is the 
transcriptional coactivator p300 (Teufel et al., 2007). Interaction with p300 via its 
TAD region is essential for the transcriptional functions of p53 (Avantaggiati et al., 
1997; Gu et al., 1997; Scolnick et al., 1997). Interestingly, the sequence within 
the p53 TAD, which is responsible for interacting with two negative regulators, 
murine double minute 2 (Mdm2) and murine double minute 4 (Mdm4), overlaps 
the p300-binding site of p53 (Kussie et al., 1996; Popowicz et al., 2007; Teufel et 
al., 2007). In addition, Mdm proteins compete with p300 for binding to the TAD of 
p53 (Teufel et al., 2007). Therefore, the relative concentrations of these factors 
and their affinities of binding to the p53 TAD in certain cellular contexts dictate 
the activation or inhibition of p53 transcriptional functions (Joerger and Fersht, 
2008). 
The PRD of human p53 contains 5 PXXP motifs (where P stands for proline 
and X for any amino acid) and serves as a link between the TAD and DBD 
(Walker and Levine, 1996). In general, PXXP motifs mediate protein-protein 
interactions via binding to Src homology 3 (SH3) domains (Feller et al., 1994). 
Although it was demonstrated that p53 PXXPs impact on interaction with p300, 
peptidyl-prolyl isomerase Pin1, transcriptional corepressor mSin3A, and Mdm2 
(Berger et al., 2001; Dornan et al., 2003; Zacchi et al., 2002; Zheng et al., 2002; 
Zilfou et al., 2001), the exact function of the PRD in p53 transactivation remains 
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largely unclear. Deletion of PRD significantly increases p53 sensitivity to Mdm2-
mediated degradation and reduces transcriptional activities in mice (Toledo et al., 
2006); however, disruption of the Pin1 binding sites or removal of PXXP motifs in 
the PRD did not significantly affect tumor suppression activities of p53 (Toledo et 
al., 2007). These data together suggest that the structure but not the primary 
sequence of PRD is essential for the functions of p53, which also explains for 
lack of conservation of PXXP motifs within the PRD among mammalian p53s 
(Toledo et al., 2007).  
The p53 DBD, which mediates the interaction of p53 with specific DNA 
sequences, resides in the middle region of the p53 protein (Bargonetti et al., 
1991; el-Deiry et al., 1992; Kern et al., 1991; Pavletich et al., 1993; Zambetti et 
al., 1992). The consensus sequence of the double-stranded DNAs that p53 binds 
contains two half-site palindromes 5’-PuPuPuC(A/T)(T/A)GPyPyPy-3’ (Pu 
represents A or G and Py for C or T) separated by a spacer sequence with 0-13 
base pairs in length (el-Deiry et al., 1992). Crystallography has revealed that two 
p53 DBDs form a dimer to bind one of these two half sites (Kitayner et al., 2006). 
Due to the critical roles of p53 DBD in mediating p53-DNA interaction, mutations 
in p53 DBD disrupt its interaction with the target DNA sequence, and therefore 
compromise the transcriptional activity of p53. In human cancer cases, over 80% 
of p53 mutations are identified in the DBD domain (Olivier et al., 2002; Petitjean 
et al., 2007), suggesting the importance of DNA binding to p53 functions.  
Early studies have clearly demonstrated that p53 binds to target DNA 
sequences as a tetramer (Friedman et al., 1993; Wang et al., 1994). The TET 
7 
domain at the C-terminus of p53, spanning residues 324-356, mediates the 
tetramerization of p53 proteins (Sakaguchi et al., 1997; Veprintsev et al., 2006). 
Although deletion of the TET domain does not completely abolish DNA-binding 
ability and transcriptional activity of p53, p53 with TET domain deletion binds to 
DNA with 10-100 times lower affinity (Chene, 2001), suggesting the importance 
of tetramerization to p53 functions. In addition, the TET domain mediates protein-
protein interactions between other proteins, such as casein kinase 2 and Ca2+-
dependent protein kinase C, which are also important for p53 regulation (Chene, 
2001).  
The CT domain of p53 represents an intrinsically unfolded structure at its C-
terminus, consisting of the last 30 amino acid residues of p53 (Joerger and 
Fersht, 2008). Deletion of the CT domain leads to the constitutive activation of 
p53 (Halazonetis and Kandil, 1993; Hupp et al., 1992), suggesting that it 
negatively regulates p53 function. In response to stress, the p53 CT domain 
undergoes extensive posttranslational modifications including phosphorylation, 
acetylation, and ubiquitination (Jimenez et al., 1999). Although it is postulated 
that these modifications are critical for p53 activation or stability, emerging in vivo 
evidence suggest that they may only contribute to the fine-tuning of p53 stress 
responses but are dispensable for p53 stability and transactivation (Krummel et 
al., 2005). 
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Biological Functions of p53 
Under normal conditions, p53 remains dormant (Vogelstein et al., 2000). It is 
only activated in response to a number of intra- and extra-cellular insults 
including but not limited to DNA damage, oncogene activation and hypoxia 
(Vogelstein et al., 2000; Vousden and Lu, 2002). Cells exposed to such stresses 
are prone to becoming neoplastic, since they are more likely to accumulate 
mutations and/or undergo aberrant proliferation compared to unstressed cells 
(Vogelstein et al., 2000). In order to maintain genomic integrity at both single cell 
and organism levels, the p53 protein, activated in these cells, functions to induce 
apoptosis, cell cycle arrest and cellular senescence via transactivating a set of 
target genes involved in such cellular programs (such as Noxa and Puma for 
apoptosis, p21 and GADD45 for cell cycle arrest, and p21 and PML for cellular 
senescence) (Figure 2) (de Stanchina et al., 2004; Hofseth et al., 2004; 
Vogelstein et al., 2000; Vousden and Lu, 2002).  
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Figure 2. Function and Activation of p53. A variety of stresses including DNA 
damage, oncogene activation, and hypoxia activate p53 through upstream stress 
sensor proteins. Activated p53 induces expression of a set of target genes 
involved in apoptosis, cell cycle arrest, and senescence. Several p53 targets, 
such as Mdm2, COP1 and Pirh2, negatively regulate p53 function, which form 
negative feedback loops. Other proteins Mdm4, ARF-BP1, and Trim24 also 
negatively regulate p53 functions. 
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Cell cycle arrest 
Cell cycle arrest is one of the first responses induced by p53 activation in 
nearly every type of mammalian cells (Vogelstein et al., 2000). Mechanically, p53 
stimulates cell cycle arrest via transactivating its major cell cycle arrest target p21 
(el-Deiry et al., 1993), which functions as a cycle-dependent kinase (CDK) 
inhibitor (Warfel and El-Deiry, 2013). As a member of the Cip/Kip family of CDK 
inhibitors, p21 interacts with and inhibits a broad spectrum of CDKs such as 
CDK2, CDK4, CDK6 and possibly CDK1 (Harper et al., 1995), and thus blocks 
cell cycle at the G1/S and G2/M transitions (Niculescu et al., 1998). Other p53 
target genes such as GADD45 and 14-3-3σ have also been reported to induce 
cell cycle arrest (Chan et al., 1999; Kastan et al., 1992; Laronga et al., 2000; 
Wang et al., 1999). However, unlike p21, GADD45 and 14-3-3σ proteins can only 
inhibit the CDK1/cyclin B1 complex, and therefore induce a G2/M but not a G1/S 
arrest (Chan et al., 1999; Laronga et al., 2000; Wang et al., 1999). In human 
tumors, the identification of the p53 mutant p53R175P (arginine to proline at 
codon 175) that lacks apoptotic activity but retains cell cycle arrest activity 
(Ludwig et al., 1996; Rowan et al., 1996) allowed examination of the tumor-
suppressive role of p53-induced cell cycle arrest. This question was clearly 
answered with the generation of knock-in mice carrying the p53515C allele that 
mimic the human p53R175P mutant. The p53515C/515C mice, although prone to 
tumor development, have a much later tumor onset compared with p53−/− mice 
(Liu et al., 2004), indicating the tumor-suppressive activity of p53-induced cell 
cycle arrest. 
11 
 
Cellular senescence 
The role of p53 in inducing cellular senescence was clearly demonstrated in 
cells overexpressing oncogene H-rasG12V (Serrano et al., 1997). Ectopic 
expression of H-rasG12V in both rodent and human cells leads to cellular 
senescence accompanied by accumulation of p53 protein; deletion of p53 
rescues the cells from senescence (Serrano et al., 1997), indicating a p53-
dependent cellular senescence in response to oncogene activation. More 
recently, two independent studies showed that p53 restoration in liver 
carcinomas and sarcomas also resulted in cellular senescence in tumors, 
suggesting that p53 exerts tumor-suppressive activity by playing a causal role in 
induction of senescence in vivo (Ventura et al., 2007; Xue et al., 2007). Although 
the mechanisms by which p53 induces the senescence program remain largely 
unclear, both in vitro and in vivo studies suggest that p21 functions as the 
senescence effector (Bearss et al., 2002; Brown et al., 1997; el-Deiry et al., 
1993).  
 The response to p53 activation varies in different contexts. For example, 
in response to DNA damage, p53 induces apoptosis in radiosensitive tissues 
such as spleen, thymus and hematopoietic system, and elicits cell cycle arrest 
and cellular senescence in other tissues such as fibroblasts and connective 
tissues (Di Leonardo et al., 1994; Kuerbitz et al., 1992; Lowe et al., 1993; Tsai et 
al., 2009). The molecular basis underlying context-dependent p53 responses 
remains largely unsolved. It has been speculated that p53 levels may serve as 
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one of the determinants dictating p53-induced responses. This notion is based 
on the finding that the promoters of cell cycle arrest/senescence genes show 
high affinity to p53, and low-affinity is observed for the promoters of apoptotic 
genes (Kaeser and Iggo, 2002; Weinberg et al., 2005). Therefore, cell cycle 
arrest/senescence but not apoptosis is likely to be induced in cells expressing 
low levels of p53, and the apoptosis pathway is activated when p53 is present at 
high levels. This is supported by a study in a hepatocellular carcinoma (HCC) cell 
line. Ectopically expressing p53 at high levels in HCC cells induces apoptosis, 
and low level p53 expression only evokes cell cycle arrest (Lai et al., 2007). 
Survival cytokines, e.g. IL-6, block p53-induced apoptosis (Liebermann et al., 
2007), suggesting that distinct factors expressed by different cells may determine 
which pathways are activated by p53. 
 
Apoptosis 
Since first observed in the myeloid leukemia cells, overexpression of wild-
type p53 has been reported to induce apoptosis in a wide range of cell types 
(Gottlieb and Oren, 1998; Yonish-Rouach et al., 1991). These observations 
provided the first set of evidence that high levels of p53 are capable of triggering 
apoptosis. In other studies, overexpression of adenovirus 5 oncogene E1A 
stabilizes endogenous wild-type p53 proteins in cells and elicits p53-dependent 
apoptosis (Debbas and White, 1993; Lowe and Ruley, 1993). Moreover, DNA 
damage caused by ionizing radiation or etoposide (a topoisomerase II inhibitor) 
also leads to induction of apoptosis in wild-type but not p53−/− thymocytes (Clarke 
13 
et al., 1993; Lowe et al., 1993). Together, these data convincingly documented a 
role for p53 in induction of apoptosis. 
p53 induces apoptosis through both transcription-dependent and -
independent pathways (Hofseth et al., 2004). Upon activation, p53 binds to the 
promoter regions of a set of proapoptotic genes such as Puma, Noxa, Bax, 
APAF-1, Fas and PIDD, and then induces the expression of such genes 
(Miyashita et al., 1994; Moroni et al., 2001; Nakano and Vousden, 2001; Oda et 
al., 2000). Upregulation of these gene products promotes activation of intrinsic or 
extrinsic apoptosis pathways (Haupt et al., 2003). As to the transcription-
independent pathway, p53 directly interacts with anti-apoptotic proteins Bcl-2 and 
Bcl-XL, inhibits their activity, and promotes the release of cytochrome c, which 
activates the intrinsic pathway (Mihara et al., 2003). Thus, p53 is directly 
engaged in induction of an apoptosis program, which is essential for its tumor 
suppressive functions. 
 
Activation of p53 
As aforementioned, p53 can be activated by various stresses including DNA 
damage, oncogene activation and hypoxia (Vogelstein et al., 2000; Vousden and 
Lu, 2002). Although a limited number of studies suggest that p53 activation 
occurs at transcriptional or translational levels (Galban et al., 2003; Wang et al., 
2004), stress signals mostly induce p53 activation at the protein level.   
Intracellular and extracellular stress stimuli sensed by upstream factors 
activate different downstream pathways, which in turn stabilize and activate p53. 
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Among such pathways activating p53, responses to oncogenic insults and DNA 
damage have been best studied. Activation of oncogenes such as Ras and c-
Myc results in upregulation of tumor suppressor ARF (Ozenne et al., 2010).  In 
turn, ARF binds to two negative inhibitors of p53, Mdm2 and ARF-BP1, and 
releases p53 from their talons, which leads to elevated p53 levels and thus 
activation of p53 (Dai et al., 2006; Ozenne et al., 2010). In response to DNA 
damage caused by IR (ionizing radiation) or UV (ultraviolet light), ATM (Ataxia 
telangiectasia mutated) and ATR (Ataxia telangiectasia and Rad3 related) 
kinases are activated (Motoyama and Naka, 2004). ATM and ATR activate p53 
by directly phoshorylating p53 at Ser15 and Ser20 or via two other kinases CHK1 
and CHK2 (Motoyama and Naka, 2004). Phosphorylation at these sites disrupts 
the interaction between p53 and Mdm2 and thus blocks Mdm2-mediated p53 
degradation, which leads to the stabilization and activation of p53 (Motoyama 
and Naka, 2004). Although HIF-1α (hypoxia-inducible factor 1α) and several 
other factors have been implicated in hypoxia-induced p53 activation (Sermeus 
and Michiels, 2011), no clear mechanism has yet been described for p53 
activation under hypoxic conditions.  
Clearly, p53 activation is a complicated but tightly controlled process 
involving a number of distinct pathways and numerous factors. Such fine 
regulation of p53 activation ensures that p53 remains inactive under non-
stressed conditions and can be rapidly activated when cells suffer from a variety 
of insults. 
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Negative Regulators of p53 
Deletion of Mdm2 or Mdm4, negative regulators of p53, leads to p53-
dependent embryonic lethal phenotypes in mice due to elevated p53 activity 
(Jones et al., 1995; Migliorini et al., 2002; Montes de Oca Luna et al., 1995; 
Parant et al., 2001). In addition, expression of a p53 mutant with elevated activity 
in mice leads to a premature aging phenotype through p53-induced senescence 
(Tyner et al., 2002). These data collectively suggests that excessive activity of 
p53 in normal unstressed cells is detrimental to the organisms. Therefore, low 
levels of p53 activity are required for the growth of unstressed cells and normal 
development of whole organisms. Several mechanisms are in place to keep p53 
activity checked, which mainly involve ubiquitination-mediated proteasomal 
degradation and block of transactivation. To date, a number of negative 
regulators of p53 engaged in such processes have been identified, which include 
Mdm2, Pirh2, COP1, TRIM24 and ARF-BP1 for p53 ubiquitination, and Mdm2, 
Mdm4 and Pirh2 for inhibiting p53 transcriptional activity (Figure 2). Among these 
factors, Mdm2 and Mdm4 have been the most studied. 
 
Regulation of p53 Functions by Mdm2 
Mdm2 was first identified as one of these genes amplified on double minute 
chromosomes in transformed mouse NIH-3T3 fibroblasts (Fakharzadeh et al., 
1991). Biallelic deletion of Mdm2 results in an embryonic lethal phenotype in 
mice, which is completely rescued in a p53−/− background (Jones et al., 1995; 
Montes de Oca Luna et al., 1995). Deletion of Mdm2 in specific types of cells 
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such as neuronal progenitors and cardiomyocytes led to embryonic lethal 
phenotypes, which were completely rescued by deletion of p53 (Grier et al., 
2006; Xiong et al., 2006). These compelling genetic observations undeniably 
indicate that Mdm2 functions as a critical negative regulator of p53 in vivo.  
Then, the question was asked how Mdm2 regulates p53.  It has been well-
documented that Mdm2 forms a tight complex with p53, masks its transactivation 
domain, inhibits p53 transcriptional activity, and thus suppresses p53-mediated 
transactivation (Momand et al., 1992; Oliner et al., 1993). These data collectively 
indicate Mdm2 negatively regulates p53 functions by blocking its transcriptional 
activity. 
Cumulative evidence also establishes the role of Mdm2 in regulating p53 
stability. Several studies have demonstrated that Mdm2 binds to p53, mediates 
ubiquitination of p53 as an E3 ubiquitin-ligase, which in turn targets p53 for 
proteasomal degradation (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 
1997). However, the p53 protein was not constitutively stabilized in an Mdm2−/− 
background, although degradation was delayed (Ringshausen et al., 2006). This 
interesting observation indicates that Mdm2 is critical for p53 degradation but 
other proteins may also function to degrade p53.  
As a important factor controlling p53 activities, Mdm2 expression is tightly 
regulated. Transcription of Mdm2 is controlled by two distinct promoters. The 
upstream promoter P1 of Mdm2 gene drives constitutive expression of it and is 
not evidently affected by p53 (Barak et al., 1994), which may function as a critical 
means to control p53 activity in normal cells under non-stressed conditions. 
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Activated p53 binds to the p53-responsive elements within intron 1 of Mdm2 
gene and drives transcription of Mdm2 from an internal Mdm2 promoter (P2) 
(Barak et al., 1994). p53-mediated Mdm2 expression together with Mdm2-
mediated p53 degradation form a negative feedback loop, which is likely the key 
mechanism for rapid clearance of activated p53 after stress is withdrawn. A 
recent animal model has provided invaluable information on the role of both 
Mdm2 promoters in vivo. The Mdm2P2 allele carries mutations of the p53-binding 
sites in the P2 promoter and completely loses p53-induced expression but 
retains constitutive expression from the P1 promoter (Pant et al., 2013). 
Surprisingly, Mdm2P2/P2 mice are viable but extremely sensitive to IR due to 
hematopoietic failure induced by high level of p53 (Pant et al., 2013). These 
observations clearly indicate constitutive expression of Mdm2 from P1 is 
sufficient for controlling p53 protein levels under physiological conditions, but 
induced expression from P2 is required to dampen p53 activity under stressed 
conditions.  
Transcripts from both Mdm2 P1 and P2 promoters possess similar coding 
potentials (Barak et al., 1994), but translation efficiency of P2 transcript is 8-fold 
higher than that of P1 (Landers et al., 1997). This enhanced translation of Mdm2 
P2 mRNA may provide additional reinforcement to degrade p53 after its 
activation by stress. 
 
Regulation of p53 by Mdm4 
18 
Mdm4 protein shares very high similarity with Mdm2 at the primary structure 
level (Shvarts et al., 1997). Two prominent conserved domains have been 
identified between Mdm4 and Mdm2, which are the RING-finger domain at the C-
termini and the p53-binding domain at the N-termini (Shvarts et al., 1997; Shvarts 
et al., 1996).  Biallelic deletion of Mdm4 leads to an embryonic lethal phenotype 
in mice, which is also rescued in a p53−/− background (Finch et al., 2002; 
Migliorini et al., 2002; Parant et al., 2001). These observations clearly indicate 
that Mdm4 functions as a negative regulator of p53 in vivo.  Like Mdm2, Mdm4 
binds to the transactivation domain of p53 and represses its transcriptional 
activity in vitro (Shvarts et al., 1996). Upon deletion of Mdm4, expression of p53 
target genes was elevated without concomitant increase in the p53 protein level 
in Mdm2–/– MEFs (murine embryonic fibroblasts) (Francoz et al., 2006), which 
suggests that Mdm4 can suppress p53 function only by inhibiting transactivation 
but not by degradation. Consistently, overexpression of Mdm4 does not induce 
degradation of p53 (Jackson and Berberich, 2000; Stad et al., 2000). In addition, 
structural analysis indicates that Mdm4 cannot function as an active E3 ligase 
due to inability to recruit an E2 ubiquitin-conjugase (Linke et al., 2008). 
Collectively, these data indicate that Mdm4 regulates p53 activity by 
transcriptional inhibition but not degradation.  
This difference in functionality between Mdm4 and Mdm2 provides a 
plausible explanation for the different phenotypes exhibited in mice with either 
Mdm4- or Mdm2-deficiency. Loss of Mdm4 in a variety of mouse tissues results 
in a set of phenotypes distinct from that of Mdm2 (Grier et al., 2006; Valentin-
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Vega et al., 2009; Valentin-Vega et al., 2008; Xiong et al., 2007; Xiong et al., 
2006), and concomitant deletion of Mdm2 and Mdm4 leads to a more severe 
phenotype compared to loss of either gene alone. Importantly, all of these 
phenotypes are rescued by deletion of p53. Intriguingly, Mdm4–/– embryonic 
lethality can be rescued by overexpression of Mdm2 (Steinman et al., 2005), 
suggesting that Mdm2 at high levels may compensate Mdm4 loss at certain 
circumstances possibly via suppressing p53 functions. Collectively, these data 
suggest that Mdm2 and Mdm4 inhibit p53 functions in a non-overlapping fashion 
in vivo. 
 
Other Factors Mediating p53 Ubiquitination 
Although it is widely accepted that Mdm2 is the major E3 ligase targeting p53 
for degradation, recent studies suggest other ubiquitin-ligases also target p53 for 
degradation.  In a study using inducible p53, loss of Mdm2 did not completely 
inhibit but only delayed degradation of p53, indicating that p53 is subjected to 
Mdm2-independent degradation (Ringshausen et al., 2006). To date, several 
ubiquitin E3 ligases have been shown to mediate p53 degradation. A RING finger 
domain E3 ligase Pirh2 (p53-induced RING-H2) binds to p53 at the DNA binding 
domain and mediates its degradation through ubiquitination (Leng et al., 2003). 
Deletion of Pirh2 RING finger domain, blocks Pirh2-mediated p53 ubiquitination, 
but does not remove repression of p53 transactivation by Pirh2 (Leng et al., 
2003), which implies that binding of Pirh2 to p53 DBD compromises p53-DNA 
interaction. Another RING finger E3 ligase, COP1 (constitutive 
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photomorphogenesis 1), also catalyzes Mdm2-independent ubiquitination of p53 
(Dornan et al., 2004). Interestingly, both Pirh2 and COP1 are p53-inducible 
genes (Dornan et al., 2004; Leng et al., 2003), suggesting the other negative 
feedback loops other than the p53-Mdm2 feedback loop may exist to modulate 
p53 activity. A HECT domain containing E3 ubiquitin ligase ARF-BP1, and 
TRIM24 (Tripartite-motif protein 24) have been reported to target p53 for 
degradation by ubiquitination (Allton et al., 2009; Chen et al., 2005). Although 
these data collectively indicate that a number of E3 ligases mediate Mdm2-
independent degradation of p53, the roles of these proteins as negative 
regulators of p53 remain to be verified in vivo using animal models.  
 
Upregulation of Mdm2 Proteins in Tumors 
Since Mdm2 functions as a major negative regulator of the tumor suppressor 
p53, a role for Mdm2 in tumor development is not surprising. High levels of 
Mdm2 are commonly found in various types of human cancers including 
sarcomas, gliomas, melanomas, carcinomas and hematological malignancies 
(Onel and Cordon-Cardo, 2004). Clinical data demonstrate that most human 
tumors that have elevated Mdm2 levels retain wild-type p53, which lead to a 
speculation that Mdm2 overexpression and p53 mutation are mutually exclusive 
since either mechanism inactivates the p53 pathway (Manfredi, 2010). Studies in 
human soft tissue sarcomas revealed that Mdm2 gene amplification results in 
overexpression of Mdm2 in tumors, but high levels of Mdm2 also exist in tumors 
lacking gene amplification of Mdm2 (Patterson et al., 1997), suggesting that other 
21 
mechanisms may contribute to Mdm2 upregulation in tumors. These 
mechanisms include increased transcription, prolonged mRNA half-life, 
enhanced translation potential and altered posttranslational modifications 
(Manfredi, 2010; Marine, 2011; Marine and Lozano, 2009; Riley and Lozano, 
2012). Extensive studies also indicate that Mdm2 upregulation by such 
mechanisms is tightly associated with tumorigenesis and tumor progression 
(Manfredi, 2010; Marine, 2011; Marine and Lozano, 2009; Riley and Lozano, 
2012).  
A number of mouse models have been established to interrogate the role of 
Mdm2 overexpression in tumorigenesis. Mdm2 transgenic (Mdm2Tg) mice were 
established using a cosmid containing the entire Mdm2 gene including the 
promoter region, and therefore resembled Mdm2 gene amplification in human 
cancers (Jones et al., 1998). An average 4-fold increase of Mdm2 expression in 
a variety of tissues of the Mdm2Tg mice leads to development of multiple types of 
tumors that include a high percentage of lymphomas and sarcomas (Jones et al., 
1998). Interestingly, Mdm2Tg/Tg mice have significantly earlier onset of tumors 
compared to Mdm2Tg mice (Jones et al., 1998), suggesting an Mdm2-dose-
dependent effect during tumorigenesis possibly through inhibition of p53 activities. 
Overexpression of Mdm2 in mouse mammary glands and skin also results in 
development of spontaneous tumors (Alkhalaf et al., 1999; Ganguli et al., 2000; 
Lundgren et al., 1997). A human Mdm2 single nucleotide polymorphism SNP309 
(T to G) is associated with earlier tumor onset in both sporadic and hereditary 
cancer patients (Bond et al., 2004). SNP309 results in enhanced transcription of 
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Mdm2 by generating an additional binding site for transcriptional activator Sp1, 
and therefore dampens p53 activity (Bond et al., 2004). Knock-in mice with a 
humanized Mdm2 intron 1 harboring SNP309 also show accelerated tumor 
development in both p53 wild-type and mutant backgrounds (Post et al., 2010). 
Collectively, these genetic mouse models reveal a causal role of Mdm2 
overexpression in tumorigenesis. 
 
p53 Reactivation in Cancer Therapy 
Since the tumor suppressor gene p53 is mutated in over 50% of human 
cancer cases and the p53 pathway is also muted by other means (e.g. 
overexpression of Mdm2) in a large number of tumors, the question was asked 
whether reactivation of p53 in these tumors could suppress tumor growth or lead 
to tumor regression. To date, several approaches have been applied to 
reactivate p53 in tumors.  
 
Targeting Mdm2 to Reactivate p53 
Since the p53 inhibitor Mdm2 is overexpressed in multiple types of human 
tumors, inhibition of Mdm2 activity may constitute a means for reactivating p53 in 
cancer cells. The finding that a 20% decrease in Mdm2 levels leads to tumor 
suppression without adverse side effects (Mendrysa et al., 2006) provides 
supportive evidence for targeting Mdm2 in cancer therapy. Extensive efforts have 
been advancing this approach rapidly. 
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A group of small molecules including nutlins, benzodiazepinediones and MI-
63/MI-219 have been identified through structure-based design and high 
throughput screening (Ding et al., 2006; Grasberger et al., 2005; Shangary et al., 
2008; Vassilev et al., 2004). Such molecules occupy the p53-binding pocket of 
Mdm2 and therefore disrupt Mdm2-p53 interaction (Ding et al., 2006; Grasberger 
et al., 2005; Shangary et al., 2008; Vassilev et al., 2004). Administration of these 
small molecules to a variety of tumors with wild-type p53 leads to accumulation 
of p53 protein and p53-induced cell cycle arrest and/or apoptosis (Ding et al., 
2006; Grasberger et al., 2005; Shangary et al., 2008; Vassilev et al., 2004). More 
interestingly, treatment with nutlin-3 and MI-219 also results in tumor suppression 
in xenograft tumor models with no noticeable adverse side effects (Shangary et 
al., 2008; Vassilev et al., 2004). Another small molecule RITA (reactivation of p53 
and induction of tumor cell apoptosis) binds to the p53 N-terminus and blocks the 
access of Mdm2 to p53 (Issaeva et al., 2004). RITA also induces accumulation of 
p53 and p53-mediated tumor suppressive activities in both p53 wild-type tumor 
cells and xenograft tumors (Issaeva et al., 2004).  Two molecules HLI98 and 
JNJ-26854165  targeting the E3 ligase activity of Mdm2 promote stabilization of 
p53 and thus suppress the growth of tumor cells or mouse xenografts, 
respectively (Yang et al., 2005) (Arts et al., 2008). Currently, phase I clinical 
studies of JNJ-26854165 (NCT00676910) and a nutlin family member RG7112 
(NCT01143740, NCT01164033, NCT00559533, NCT00623870 and 
NCT01605526) have shown acceptable safety of both drugs in patients with 
multiple types of tumors (Andreeff et al., 2010; Andreeff et al., 2011; Beryozkina 
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et al., 2011; Kurzrock et al., 2012; Ray-Coquard et al., 2011; Tabernero et al., 
2009). In particular, RG7112 treatment of patients with leukemias, lymphomas, 
sarcomas and other solid tumors have shown favorable clinical outcomes 
including induction of apoptosis, reduced cell proliferation and complete 
remission (Andreeff et al., 2010; Andreeff et al., 2011; Beryozkina et al., 2011; 
Kurzrock et al., 2012; Ray-Coquard et al., 2011). 
Although exciting, there are a number of caveats in the use of these drugs, 
which may limit their applications in clinic. First, the therapeutic effectiveness of 
these drugs is totally dependent on the presence of wild-type p53 in tumors, 
since no p53-induced tumor suppressive activities have been observed in the 
tumor cells with mutant p53 (Ding et al., 2006; Grasberger et al., 2005; Issaeva 
et al., 2004; Shangary et al., 2008; Vassilev et al., 2004) . However, over 50% 
human cancers have p53 mutations, and more importantly a very high 
percentage of tumors carrying p53 mutations undergo loss-of-heterozygosity 
(LOH) (Bellini et al., 2012; Coles et al., 1992; Fenoglio-Preiser et al., 2003; 
Venkatachalam et al., 2001). Therefore, wild-type p53 is not present in a large 
proportion of tumors, which will severely limit the administration of these drugs 
only to cancer patients carrying wild-type p53. Second, it is well-documented that 
Mdm2 also binds and degrades mutant p53 (Lukashchuk and Vousden, 2007; 
Midgley and Lane, 1997; Terzian et al., 2008). Disrupting the interaction of 
mutant p53 with Mdm2 will lead to the stabilization of mutant p53 (Lukashchuk 
and Vousden, 2007; Terzian et al., 2008) that possess gain-of-function 
oncogenic activities (Lang et al., 2004; Midgley and Lane, 1997; Olive et al., 
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2004; Terzian et al., 2007). Therefore, administration of these Mdm2 inhibitors 
even to patients with both wild-type and mutant p53 alleles may lead to 
unfavorable responses. Lastly, in the preclinical studies, treatment with Mdm2-
inhibitors resulted in accumulation of considerable amount of Mdm2 (Ding et al., 
2006; Grasberger et al., 2005; Graves et al., 2012; Issaeva et al., 2004; Koblish 
et al., 2006; Tovar et al., 2006; Vassilev et al., 2004; Yang et al., 2005). Since 
p53-independent oncogenic activities of Mdm2 have been well documented (Li 
and Lozano, 2013), accumulation of Mdm2 by administration of Mdm2 inhibitors 
may also cause detrimental effects to the patients. Therefore, caution should be 
taken when administrating Mdm2 inhibitors to patients, and the safety, efficacy 
and effectiveness of these inhibitors should be monitored closely. 
 
Gene delivery of wild-type p53 
As aforementioned, in an early study, overexpression of wild-type but not 
mutant p53 in a murine myeloid leukemic cell line that lacks p53 resulted in 
induction of rapid apoptosis (Yonish-Rouach et al., 1991), suggesting that 
reactivation of p53 is an effective strategy to treat tumors with loss of p53 
activities. Delivery of exogenous wild-type p53 into tumor cells with p53 loss 
using retroviral vectors leads to growth suppression in both human cancer cell 
lines and orthotopic mouse models (Cai et al., 1993; Fujiwara et al., 1994). 
These data together indicate that reactivation of p53 may serve as an effective 
therapeutic strategy in human cancers. 
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Recently, four research groups have independently established genetically 
engineered mice using distinct approaches, which allow p53 restoration in vivo. 
Utilizing these mice as tools, p53 restoration in established tumors has been 
modeled for multiple types of tumors (Martins et al., 2006; Ventura et al., 2007; 
Wang et al., 2011; Xue et al., 2007). Martins and colleagues evaluated the 
effects of p53 restoration in an Eµ-Myc mouse model to address the question 
whether p53 loss is required for tumor maintenance in lymphomas (Martins et al., 
2006). To this end, they used a specific p53 knock-in allele (p53KI), which 
encodes a wild-type p53 protein fused with a modified form of estrogen receptor 
(p53ER). This fusion protein can be only activated when 4-hydroxytamoxifen is 
administrated; otherwise, p53ER remains inactive in the cytoplasm. Activated 
p53ER enters the nucleus and functions as wild-type p53. A proportion of B-cell 
lymphomas developed in Eµ-Myc p53KI/+ mice underwent LOH and became 
tumors of an Eµ-Myc p53KI/0 genotype, in which p53 was functionally null. When 
transplanted into syngeneic mice, Eµ-Myc p53KI/0 lymphomas developed rapidly. 
However, 4-hydroxytamoxifen administration led to regression of these Eµ-Myc 
p53KI/0 lymphomas by p53-mediated apoptosis, which also extended the survival 
of tumor-carrying mice. Interestingly, tumors resistant to 4-hydroxytamoxifen 
showed deletion of Arf or p53KI after short-term p53 restoration, implying a 
powerful selection against the p53 pathway.  
Ventura and colleagues addressed the same question using a distinct 
mouse model (Ventura et al., 2007). In this study, they generated a p53 allele 
(p53LSL) with a loxP-flanked STOP cassette inserted in the intron 1 of the p53 
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locus. p53 expression from p53LSL is normally blocked by the STOP cassette, but 
restored when Cre recombinase recognizes loxP sites and removes the STOP 
cassette. p53LSL/LSL and p53LSL/LSL Cre-ERT2 mice develop spontaneous 
lymphomas and sarcomas rapidly. p53 restoration by tamoxifen-activated Cre-
ERT2 led to tumor regression in p53LSL/LSL Cre-ERT2 tumors. However, tamoxifen 
injection did not suppress p53LSL/LSL tumor progress, since no p53 expression 
was restored. Inttriguingly, tumor-specific responses to p53 restoration were 
observed in this study. Upon p53 restoration, lymphomas showed apoptosis 
predominantly, and sarcomas showed senescence.  
In another study, Xue and colleagues evaluated therapeutic efficacy of 
p53 restoration in a transplant murine liver carcinoma model (Xue et al., 2007). 
H-RasV12 transformed embryonic liver cells with repressed p53 expression by 
shRNA formed liver carcinomas quickly when transplanted into 
immunocompromised mice. p53 restoration by turning off shRNA expression led 
to complete regression of these liver carcinomas.  
Wang et al. (2011) modeled p53 restoration in the presence of mutant p53 
allele p53515A (encoding the p53R172H mutant protein) in spontaneous 
lymphomas and sarcomas. They generated a hypomorphic p53 allele (p53Neo) 
with loxP-flanked PGKneo cassette inserted in the intron 4 of the p53 locus. p53 
expression from p53Neo is repressed by the PGKneo cassette under normal 
conditions, and restored to wild-type levels when active Cre recombinase 
removes the PGKneo Cassette. p53 restoration by tamoxifen-activated Cre-ER 
resulted in tumor regression in p53Neo/− Cre-ER tumors, while p53 restoration in 
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p53Neo/515A Cre-ER tumors only led to tumor stasis, suggesting that mutant 
p53R172H partially inhibits the restored wild-type p53 in the tumors. These four 
studies together indicate that p53 restoration in vivo renders tumor suppression 
and therefore supports the concept that p53 gene delivery is an effective 
approach for cancer treatment.  
 
p53 Restoration in an Mdm2-overexpressing Background 
Clinical data demonstrate that a large number of human tumors have 
elevated Mdm2 levels but lack p53 mutations (Momand et al., 1998; Oliner et al., 
1992), which suggest Mdm2 overexpression and p53 mutations are mutually 
exclusive since either mechanism inactivates the p53 pathway (Manfredi, 2010; 
Momand et al., 1998). Accumulating evidence also indicates that a proportion of 
human tumors exist, which feature both Mdm2 overexpression and loss of wild-
type p53 (Alazzouzi et al., 2007; Burton et al., 2002; Ganly et al., 2000; Gorgoulis 
et al., 2000; Gorgoulis et al., 1996; Gunther et al., 2000; Jablkowski et al., 2005; 
Jiao et al., 2002; Li et al., 2000; Marks et al., 1996; Ohnstad et al., 2013; 
Watanabe et al., 1994). More interestingly, patients with tumors carrying both 
alterations generally show more malignant disease and poorer prognosis, 
compared to the ones with tumors bearing either alteration alone (Gorgoulis et 
al., 2000; Gorgoulis et al., 1996; Li et al., 2000; Marks et al., 1996). These 
observations suggest that alterations in both Mdm2 and p53 may confer 
additional growth advantages to tumor cells.  
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Previously, Jones et al demonstrated that Mdm2Tg mice with an average 
4-fold increase in Mdm2 levels compared to wild-type mice developed tumors 
with 100% penetrance and long latency (Jones et al., 1998). The tumor onset in 
Mdm2Tg p53−/− mice, occurred much earlier than that in Mdm2Tg mice, but 
showed no difference from that in p53−/− mice (Jones et al., 1998). Currently, 
there is no direct evidence showing that elevated Mdm2 levels and dampened 
p53 expression additively contribute to tumorigenesis in vivo. Moreover, 
coexistence of Mdm2 overexpression and loss of wild-type p53 in tumors raises a 
question whether restoration of wild-type p53 expression in tumors with both 
alterations will alleviate the diseases. The p53Neo allele developed in our 
laboratory serves as a unique tool to examine these two questions in vivo. First, 
as a hypomorphic allele, p53Neo expresses wild-type p53 at a very low level, 
which provides the best opportunity to test the suppression imposed on already 
decreased p53 levels by high levels of Mdm2. Second, the p53Neo allele can be 
converted to a fully functional p53 allele at will by addition of active Cre 
recombinase, which well serves the purpose of restoring wild-type p53 
expression in established tumors. 
To this end, I established a mouse model with ectopic expression of 
Mdm2 and dampened expression of p53 to examine the combinational effects of 
these two alterations on tumorigenesis and subsequently to investigate 
therapeutic efficacy of p53 restoration in tumors with high Mdm2 levels. In this 
dissertation, I demonstrated that high levels of Mdm2 and low levels of p53 act 
additively to dampen p53 activity in DNA damage response and tumor 
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development.  Our data indicate that restoration of wild-type p53 expression in 
Mdm2-overexpressing angiosarcomas resulted in tumor stasis and regression in 
some cases. I further showed that the restored p53 suppressed cell proliferation 
in the Mdm2-overexpressing angiosarcomas but did not elicit apoptosis. 
Therefore, I conclude that restoration of wild-type p53 expression represents a 
potential strategy to treat tumors with high levels of Mdm2.  
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CHAPTER 2. RESULTS 
 
Additive Effects of Mdm2 Overexpression and Decreased p53 Expression  
 
Mdm2Tg mice carrying an integrated Mdm2 cosmid and expressing on 
average 4-fold higher levels of Mdm2 compared to that of wild-type mice, are 
tumor prone (Jones et al., 1998), while the p53Neo/Neo mice inheriting two copies 
of a hypomorphic p53 allele have decreased expression of wild-type p53 and are 
also tumor prone (Wang et al., 2011). To test whether Mdm2 overexpression and 
decreased p53 levels will combinatively affect p53 function, I crossed Mdm2Tg 
mice with p53Neo/Neo mice to generate Mdm2Tg p53Neo/Neo mice. Since the Mdm2 
transgene in the Mdm2Tg mice is under control of its native promoter (Jones et al., 
1998) and p53 drives the expression of Mdm2 from its P2 promoter (Barak et al., 
1994), it was of interest to see whether the hypomorphic p53Neo allele with 
dampened p53 expression will affect expression of Mdm2 in the Mdm2Tg 
p53Neo/Neo mice. Therefore, I measured the Mdm2 mRNA level by quantitative 
real-time PCR (qRT-PCR) in wild-type, p53Neo/Neo, Mdm2Tg, Mdm2Tg p53Neo/Neo 
mice in the spleen, a radiosensitive tissue. As shown in Figure 3, the Mdm2 
transcript levels in the spleens of Mdm2Tg p53Neo/Neo mice were comparable with 
that of Mdm2Tg mice, and approximately 4-fold higher than that of wild-type and 
p53Neo/Neo mice, suggesting that the p53 status did not affect expression of the 
Mdm2 transgene under physiological conditions.  
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Figure 3. Mdm2 overexpression in Mdm2Tg and Mdm2Tg p53Neo/Neo mouse 
spleens. qRT-PCR analysis of Mdm2 mRNA levels in the spleens from 4-6 week 
old mice with wild-type (WT) (n=5), p53Neo/Neo (N/N) (n=4), Mdm2Tg  (M2Tg) (n=3), 
and Mdm2Tg p53Neo/Neo (M2Tg N/N) (n=4) genotypes. Data were normalized to 
expression in a wild-type spleen and represent a mean± SEM.  
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To verify that high levels of Mdm2 further dampens the p53 protein levels 
in the Mdm2Tg p53Neo/Neo mice with already decreased p53 levels, I compared the 
p53 protein levels in the wild-type, Mdm2Tg, p53Neo/Neo, and Mdm2Tg p53Neo/Neo 
mice. Since p53 levels are undetectable under normal conditions, I treated these 
mice with 6 Gy IR to stabilize p53 in the animals. Upon IR treatment, less p53 
was stabilized in the spleens of Mdm2Tg and p53Neo/Neo mice compared to that of 
wild-type spleens, and p53 levels in the IR-treated Mdm2Tg p53Neo/Neo mouse 
spleens were even less than that in Mdm2Tg and p53Neo/Neo spleens (Figure 4). 
To further test whether the reduced levels of p53 protein in the Mdm2Tg p53Neo/Neo 
mice affect its transcriptional activity, I compared the mRNA levels of p53 target 
genes p21 and Puma in the spleens of wild-type, Mdm2Tg, p53Neo/Neo, and 
Mdm2Tg p53Neo/Neo mice after IR treatment. There was an over 40-fold increase in 
the p21 mRNA levels in the IR-treated wild-type mouse spleens compared to that 
of the untreated wild-type spleens. Induction of p21 by IR was significantly 
reduced in Mdm2Tg and p53Neo/Neo spleens and further dampened in Mdm2Tg 
p53Neo/Neo mouse spleens compared to wild-type spleens (Figure 5). A similar 
pattern was also observed for the other p53 target gene Puma (Figure 5). These 
data together indicate that Mdm2 overexpression and decreased p53 levels 
additively compromise p53 function during DNA damage response.  
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Figure 4. p53 protein levels in IR treated mouse spleens. Western blot 
analysis of p53 expression in the spleens of IR (6 Gy)-treated 4-6 week old mice 
with wild-type (WT), p53Neo/Neo (N/N), Mdm2Tg (M2Tg), and Mdm2Tg p53Neo/Neo 
(M2Tg N/N) genotypes. For each genotype, protein lysate samples from 3 mouse 
spleens were pooled together. Protein lysate from an Mdm2−/− p53−/− spleen 
served as negative control. The number under each lane indicates the relative 
p53 levels compared to wild-type (set as 100%). 
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Figure 5. Induction of p53 target genes by IR in mice with different 
genotypes.  qRT-PCR analysis of mRNA levels of p53 target genes p21 and 
Puma in the spleens from 4-6 week old wild-type (WT) (n=5), p53Neo/Neo (N/N) 
(n=4), Mdm2Tg (M2Tg) (n=3), and Mdm2Tg p53Neo/Neo (M2Tg N/N) (n=4) mice with 
or without 6 Gy IR treatment. Data were normalized to expression in a wild-type 
spleen without IR treatment and represent a mean± SEM. 
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To examine the additive effects of Mdm2 overexpression and p53 loss in 
tumorigenesis, I established Mdm2Tg, p53Neo/Neo, and Mdm2Tg p53Neo/Neo mouse 
cohorts for tumor studies. Interestingly, Mdm2Tg p53Neo/Neo mice showed a 
significant shorter tumor latency (348 days) compared to that of Mdm2Tg (666 
days) and p53Neo/Neo mice (484 days) (Figure 6 and Table 1), indicating that 
Mdm2 overexpression and p53 loss cooperate to accelerate tumor formation. 
The most common tumor types observed in these mice were lymphomas and 
sarcomas (Table 2).  
In summary, I established a cohort of Mdm2Tg p53Neo/Neo mice, which has 
lower p53 levels and activities compared with Mdm2Tg and p53Neo/Neo mice. 
Moreover, Mdm2Tg p53Neo/Neo mice have earlier tumor onset than Mdm2Tg or 
p53Neo/Neo mice. 
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Figure 6. Tumor-free survival curves of p53Neo/Neo, Mdm2Tg, and Mdm2Tg 
p53Neo/Neo mice. Numbers in the brackets indicate numbers of mice in the given 
cohorts. p-values indicate the difference between two survival curves. Difference 
between survival curves was determined via Log-rank (Mantel-Cox) test. 
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Table 1. Median Tumor-free survival of p53Neo/Neo, Mdm2Tg, and Mdm2Tg 
p53Neo/Neo mice. 
Median  
Tumor-free  
Survival 
p53Neo/Neo Mdm2Tg Mdm2Tg p53Neo/Neo 
Days 484 666 348 
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Table 2. Tumor spectra of p53Neo/Neo, Mdm2Tg and Mdm2Tg p53Neo/Neo mice. 
  
Tumor Types 
Genotypes 
p53Neo/Neo 
(n=19) 
Mdm2Tg 
(n=24) 
Mdm2Tg 
p53Neo/Neo 
(n=44) 
Lymphoma  7 (28.0%) 16 (61.5%) 20 (35.7%) 
 
 
   
Sarcoma 
 15 (60.0%) 4 (15.4%) 28 (50%) 
Angiosarcoma 8 3  15 
Spindle cell sarcoma 5  11 
Other sarcomas 2 1 2 
 
    
Other  3 (12%) 6 (23.1%) 8 (14.3%) 
 
    
Total  25 26 56 
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p53 Restoration in Mdm2-overexpressing Cells 
 
To examine the growth suppressing effects of p53 restoration in Mdm2-
overexpressing cells, I restored p53 expression in Mdm2Tg p53Neo/Neo CreER 
MEFs using 4-hydroxytamoxifen to induce the DNA recombinase activity of 
CreER. Upon 4-hydroxytamoxifen treatment, the mRNA levels of p53 increased 
by 8-fold in the Mdm2Tg p53Neo/Neo CreER MEFs compared with that of the 
vehicle-treated control cells (Figure 7). In MTT assays, 4-hydroxytamoxifen 
treatment significantly suppressed the growth of Mdm2Tg p53Neo/Neo CreER MEFs 
compared with the vehicle-treated control (Figure 8), suggesting a correlation 
between p53 restoration and suppression of cell growth. I then investigated 
whether the p53 restoration would lead to enhanced p53 function in response to 
DNA damage. Therefore, I treated the Mdm2Tg p53Neo/Neo CreER MEFs with DNA 
damaging drug doxorubincin following 4-hydroxytamoxifen treatment. After 
treatment with doxorubicin, expression of p53 target genes p21 and Noxa in the 
4-hydroxytamoxifen-treated Mdm2Tg p53Neo/Neo CreER MEFs was significantly 
higher than that in the control cells (Figure 9). These data collectively indicate 
that p53 restoration in Mdm2-overexpressing and p53-insufficient cells can 
rescue p53 function and lead to growth suppression 
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Figure 7. p53 restoration in 4-hydroxytamoxifen-treated Mdm2Tg p53Neo/Neo 
CreER MEFs. qRT-PCR analysis of p53 expression in the Mdm2Tg p53Neo/Neo 
CreER MEFs treated with 1 µM 4-hydroxytamoxifen or vehicle control. 4OH-Tam, 
4-hydroxytamoxifen.   
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Figure 8. p53 restoration suppresses growth of Mdm2Tg p53Neo/Neo CreER 
MEFs. MTT assays of Mdm2Tg p53Neo/Neo CreER MEFs treated with 1 µM 4-
hydroxytamoxifen or vehicle control. 4OH-Tam, 4-hydroxytamoxifen.  
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Figure 9. p53 restoration led to elevated induction of p53 target genes in 
Mdm2Tg p53Neo/Neo CreER MEFs. qRT-PCR analysis of p53 target gene p21 and 
Noxa expression in the Mdm2Tg p53Neo/Neo CreER MEFs. Mdm2Tg p53Neo/Neo 
CreER MEFs treated with 1 µM 4-hydroxytamoxifen or vehicle control for 48 
hours, followed by doxorubicin (1 µg/mL) treatment for 4 hours or vehicle 
treatment. 4OH-Tam, 4-hydroxytamoxifen; Doxo, doxorubicin.  
44 
To further investigate the effects of restoring p53 under oncogene activation 
conditions, I infected Mdm2Tg p53Neo/Neo CreER MEFs with an H-RasG12V 
retrovirus. Ectopic expression of H-RasG12V led to stabilization of p53 in these 
MEFs, and p53 restoration by 4-hydroxytamoxifen treatment further resulted in 
higher p53 protein levels in H-RasG12V-infected Mdm2Tg p53Neo/Neo CreER MEFs 
compared with that of the control cells (Figure 10).  To test whether increased 
p53 levels are associated with enhanced p53 function in the H-RasG12V-infected 
Mdm2Tg p53Neo/Neo CreER MEFs, I measured expression of p53 target genes in 
these cells. The expression of p53 target genes p21 and Noxa was induced upon 
p53 restoration by 4-hydroxytamoxifen in the Mdm2Tg p53Neo/Neo CreER 
regardless of H-RasG12V infection (Figure 11). Interestingly, upon 4-
hydroxytamoxifen treatment, the expression levels of p21 and Noxa were 
significantly higher in the H-RasG12V-infected MEFs than that of control cells 
(Figure 11), suggesting that oncogene activation potentiates function of restored 
p53 in the Mdm2-overexpressing cells.  As illustrated with MTT assays, H-
RasG12V-infected Mdm2Tg p53Neo/Neo CreER MEFs grew significantly slower than 
the vehicle-treated cells upon 4-hydroxytamoxifen treatment (Figure 12). In 
addition, in the presence of 4-hydroxytamoxifen, the growth of H-RasG12V-
infected MEFs was also significantly slower than that of the cells without H-
RasG12V infection (Figure 12). These data together indicate that reintroducing p53 
expression in oncogene-overexpressing cells may confer more potent growth 
suppressing activities even in an Mdm2-overexpressing background. 
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In summary, p53 restoration in Mdm2Tg p53Neo/Neo CreER MEFs led to 
increased p53 levels, and thus elevated p53 activities in response to both DNA 
damage and oncogene activation. In addition, p53 restoration suppressed the 
growth of Mdm2-overexpressing MEFs. 
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Figure 10. p53 restoration in H-RasG12V-infected Mdm2Tg p53Neo/Neo CreER 
MEFs. Western blot analysis of p53 expression in H-RasG12V-infected Mdm2Tg 
p53Neo/Neo CreER MEFs upon 1 µM 4-hydroxytamoxifen treatment for 48 hours. 
H-Ras, H-RasG12V. 4OH-Tam, 4-hydroxytamoxifen. 
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Figure 11. Induction of p53 target genes upon p53 restoration in H-RasG12V-
infected Mdm2Tg p53Neo/Neo CreER MEFs. qRT-PCR analysis of p53 target 
genes p21 and Noxa upon 1 µM 4-hydroxytamoxifen treatment for 48 hours. H-
Ras, H-RasG12V. 4OH-Tam, 4-hydroxytamoxifen.  
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Figure 12. p53 restoration suppresses growth of H-RasG12V-infected Mdm2Tg 
p53Neo/Neo CreER MEFs. MTT assays of H-RasG12V-infected Mdm2Tg p53Neo/Neo 
CreER MEFs incubated with 1 µM 4-hydroxytamoxifen or vehicle control. H-Ras, 
H-RasG12V. 4OH-Tam, 4-hydroxytamoxifen. 
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p53 Restoration Leads to Tumor Suppression in vivo 
 
In order to examine the therapeutic effects of p53 restoration on tumors in 
vivo, I established a mouse cohort with both Mdm2Tg p53Neo/Neo CreER and the 
Mdm2Tg p53Neo/Neo genotypes. Previous studies have shown that expression of 
Cre recombinase in transgenic animals leads to developmental defects, due to 
Cre functions at non-conventional recombination sites (Forni et al., 2006; 
Loonstra et al., 2001; Schmidt et al., 2000). To test whether CreER affects tumor 
development in our mouse cohort, I compared the tumor-free survival curves 
between Mdm2Tg p53Neo/Neo CreER and the Mdm2Tg p53Neo/Neo mice. The tumor-
free survival curves of untreated mice from both genotypes overlap with each 
other (Figure 13), indicating that the presence of CreER transgene did not affect 
tumor development in the Mdm2Tg p53Neo/Neo CreER group. In order to screen 
spontaneous tumors at early stages, tumor formation in both genotypes was 
closely monitored with magnetic resonance imaging (MRI) bi-weekly. After 
tumors reached a size of >50mm3, a proportion of tumor-bearing mice underwent 
weekly tamoxifen treatment for up to 4 weeks. Three major tumor types were 
captured in the tamoxifen-treated group, which were lymphomas, spindle cell 
sarcomas, and angiosarcomas. To examine the effects of p53 restoration in 
these tumors, I first analyzed the recombination rate of p53Neo allele in the 
Mdm2Tg p53Neo/Neo CreER tumors upon tamoxifen treatment. An average of 7% 
recombination rate was observed in the lymphomas after 4 doses of tamoxifen 
treatment (Figure 14). Three treated Mdm2Tg p53Neo/Neo CreER spindle cell 
50 
sarcomas showed highly variable recombination rates ranging from 9% to 61% 
(Figure 14). The Mdm2Tg p53Neo/Neo CreER angiosarcomas had a uniform 
recombination rate with an average of 33% upon 4 doses of tamoxifen treatment 
(Figure 14). Therefore, I focused on these angiosarcomas and used them as a 
model system to study the effects of p53 restoration on Mdm2-overexpressing 
tumors (Table 3).  
To examine the therapeutic potential of p53 restoration in mice with tumors 
overexpressing Mdm2, I compared the survival curves of tumor-carrying Mdm2Tg 
p53Neo/Neo CreER and Mdm2Tg p53Neo/Neo mice during tamoxifen treatment. Upon 
tamoxifen treatment, the angiosarcoma-bearing mice of the genotype Mdm2Tg 
p53Neo/Neo CreER survived significantly longer than that of Mdm2Tg p53Neo/Neo 
(Figure 15), suggesting that p53 restoration can prolong the survival of these 
tumor-carrying mice. To examine the effects of p53 restoration in tumor 
suppression, I then compared the changes in tumor volumes (post-treatment/pre-
treatment ratio) between the Mdm2Tg p53Neo/Neo CreER and Mdm2Tg p53Neo/Neo 
groups. As shown in Figures 16 and 17, Mdm2Tg p53Neo/Neo CreER 
angiosarcomas grew slower than the Mdm2Tg p53Neo/Neo angiosarcomas upon 
tamoxifen treatment. To exclude the possibility that differences in post-
treament/pre-treatment ratios between these two mouse genotypes were due to 
the differences in initial tumor volumes, I compared the pre-treatment volumes 
(initial volumes) of angiosarcomas in both genotypes. There were no significant 
differences in tumor volumes between Mdm2Tg p53Neo/Neo CreER and Mdm2Tg 
p53Neo/Neo angiosarcomas at the time that tamoxifen treatment started (Figure 
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18), suggesting that p53 restoration by tamoxifen treatment led to growth 
suppression in the Mdm2-overexpressing angiosarcomas.  
In summary, I have established a mouse model for restoring p53 in Mdm2-
overexpressing tumors. Mdm2Tg p53Neo/Neo CreER angiosarcomas were chosen 
as a p53 restoration model system due to their significant levels of recombined 
p53Neo alleles after tamoxifen treatment. Upon p53 restoration in such tumors, 
growth suppression of tumors was observed, which is associated with prolonged 
survival of tumor-carrying mice. 
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Figure 13. Tumor-free survival curves of Mdm2Tg p53Neo/Neo and Mdm2Tg 
p53Neo/Neo CreER mice. Numbers in the brackets indicate mouse numbers in the 
given cohorts.  Median tumor-free survival of Mdm2Tg p53Neo/Neo mice is 348 days, 
and 357 days for Mdm2Tg p53Neo/Neo CreER. Difference between survival curves 
was determined via Log-rank (Mantel-Cox) test. 
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Figure 14. p53Neo recombination in tamoxifen-treated Mdm2Tg p53Neo/Neo 
CreER tumors. a, PCR analysis of recombined  p53Neo alleles in tumors treated 
with 4 doses of tamoxifen (A. angiosarcoma, L. lymphoma. S. spindle cell 
sarcoma)   b, recombination rates of p53Neo alleles calculated from Figure 14a 
using ImageJ software. 
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Table 3. List of Mdm2Tg p53Neo/Neo and Mdm2Tg p53Neo/Neo CreER 
angiosarcomas monitored in the MRI study.  
Tumor volumes are calculated from the stack of tumor MRI images; tumor 
volume changes are the fold changes of tumor volumes at the endpoint versus at 
the start point. Tumor growth rate is calculated based on the assumption that 
tumors undergo exponential growth. 
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Figure 15. Survival curves of angiosarcoma-carrying Mdm2Tg p53Neo/Neo 
CreER and Mdm2Tg p53Neo/Neo mice upon tamoxifen treatment. Numbers in 
the brackets indicate mouse numbers in the given cohorts. Difference between 
survival curves was determined via Log-rank (Mantel-Cox) test. 
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Figure 16. p53 restoration led to suppression of tumor growth in Mdm2Tg 
p53Neo/Neo CreER angiosarcomas. Tumor volume changes (post-treatment 
volume/pre-treatment volume ratio) of angiosarcomas in Mdm2Tg p53Neo/Neo 
CreER and Mdm2Tg p53Neo/Neo mice during tamoxifen treatment.   
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Figure 17. Representative MRI images of tamoxifen-treated Mdm2Tg 
p53Neo/Neo CreER angiosarcomas. Tumor MRI images and changes in tumor 
volumes of two representative angiosarcomas (Upper: Mdm2Tg p53Neo/Neo CreER; 
lower: Mdm2Tg p53Neo/Neo). Day 0, the day treatment started; day 28, 28 days 
after initial tamoxifen treatment, etc.   
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Figure 18. Initial tumor volumes of Mdm2Tg p53Neo/Neo and Mdm2Tg p53Neo/Neo 
CreER angiosarcomas. Initial tumor volume, the tumor volume when the first 
tamoxifen treatment was initiated.  
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A Syngeneic Mouse Model for p53 Restoration 
 
I then aimed to determine what types of responses occurred with restoring 
p53 in the Mdm2-overexpressing angiosarcomas. Although higher average levels 
of p53 target genes such as p21 and Mdm2 were observed in Mdm2Tg p53Neo/Neo 
CreER angiosarcomas compared to that of the Mdm2Tg p53Neo/Neo 
angiosarcomas in response to tamoxifen administration, the difference between 
two groups were not statistically significant (Figure 19). One plausible 
explanation for this unexpected observation is the heterogeneity of tumors, which 
might contribute to in-group variation and lack of differences between groups. To 
eliminate this in-group variation, I established a syngeneic tumor mouse model of 
angiosarcomas. Briefly, a spontaneous Mdm2Tg p53Neo/Neo CreER angiosarcoma 
was processed into single cell suspension, and injected into the subcutaneous 
flank regions of multiple syngeneic mice. In this transplant model, over 90% of 
p53Neo alleles in the transplant tumors were recombined upon tamoxifen 
administration (Figure 20). In agreement with previous data, the tamoxifen-
treated angiosarcomas grew significantly slower than the vehicle-treated controls 
(Figure 21). Since transplanted tumors reached the maximum allowable size 
faster in the vehicle-treated control group than that of tamoxifen-treated group, 
two groups of mice were under treatments for different durations. Therefore, the 
tumor volume changes during the treatment periods may not reflect the actual 
differences between these two groups of tumors. In order to illustrate the 
differences more accurately, I compared the tumor doubling times between the 
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tamoxifen-treated and control groups. Briefly, tumor doubling time was calculated 
based on the exponential curve fit of the tumor volume against time. The tumor 
doubling time of Mdm2Tg p53Neo/Neo CreER angiosarcomas upon tamoxifen 
administration (10.9 days) was much longer than that of Mdm2Tg p53Neo/Neo 
CreER angiosarcomas undergoing vehicle treatment (4.5 days) (Figure 22). 
These data collectively indicate a positive correlation between p53 restoration 
and tumor growth suppression in the transplant tumor model.  
In order to examine upregulation of p53 activity after p53 restoration, I 
measured the protein levels of p53 and the p53 target p21 in both tamoxifen-
treated and control Mdm2Tg p53Neo/Neo CreER angiosarcomas. p53 restoration by 
tamoxifen injection in these transplant angiosarcomas led to accumulation of p53 
and p21 proteins compared with control tumors (Figure 23). I then examined the 
induction of p53 target gene expression in the transplant tumors of Mdm2Tg 
p53Neo/Neo CreER angiosarcomas upon tamoxifen injection. In comparison to the 
untreated tumors, transplant tumors treated with tamoxifen expressed 
significantly higher levels of p53 targets p21 and Puma (Figure 24). These data 
together indicate that tamoxifen administration in the transplant Mdm2Tg 
p53Neo/Neo CreER angiosarcomas restored expression of functional p53 that led to 
elicitation of gene expression downstream to p53. 
In summary, I have established a syngeneic mouse model for p53 
restoration in Mdm2Tg p53Neo/Neo CreER angiosarcomas. p53 restoration in such 
tumors led to upregulation of p53 and p53 target genes, which suppressed the 
growth of tumors.  
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Figure 19. Induction of p53 target genes in tamoxifen-treated Mdm2Tg 
p53Neo/Neo and Mdm2Tg p53Neo/Neo CreER angiosarcomas. qRT-PCR analysis of 
p53 target gene expression in tamoxifen-treated spontaneous Mdm2Tg p53Neo/Neo 
and Mdm2Tg p53Neo/Neo CreER angiosarcomas. 1X tamoxifen, 1 dose of 
tamoxifen treatment; 4X tamoxifen, 4 doses of tamoxifen treatment. 
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Figure 20. p53Neo Recombination in transplanted Mdm2Tg p53Neo/Neo CreER 
angiosarcomas after tamoxifen treatment. PCR analysis of p53Neo allele 
recombination in two representative transplanted Mdm2Tg p53Neo/Neo CreER 
angiosarcomas upon tamoxifen treatment.  
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Figure 21. p53 restoration led to growth suppression of transplant Mdm2Tg 
p53Neo/Neo CreER angiosarcomas. Transplant tumor sizes were measured with 
digital calipers twice a week and tumor volumes were calculated using the 
equation [(width2×length)/2] as described by Bearss et al., 2000 (Bearss et al., 
2000). a) Growth curves of transplated angiosarcomas under tamoxifen and 
vehicle control treatments. b) Comparison of tumor volume changes between 
angiosarcomas undergoing tamoxifen and vehicle control treatments. 
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Figure 22. Tumor doubling times of tamoxifen-treated and control 
transplant Mdm2Tg p53Neo/Neo CreER angiosarcomas. Tumor doubling time 
was calculated based on the exponential curve fit of the tumor volume against 
time.  
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Figure 23. p53 restoration resulted in increased protein levels of p53 and 
p21 in transplanted Mdm2Tg p53Neo/Neo CreER angiosarcomas. Western blot 
analysis of p53 and p21 levels in tamoxifen-treated and vehicle control Mdm2Tg 
p53Neo/Neo CreER transplanted angiosarcomas. Three representative tumors from 
both control and tamoxifen-treated groups were examined. Mdm2−/− p53−/− spleen 
protein extract was used as a negative control.  
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Figure 24. Induction of p53 target genes upon tamoxifen treatment in 
transplanted Mdm2Tg p53Neo/Neo CreER angiosarcomas. qRT-PCR analysis of 
expression of p53 target genes (p21 and Puma) in tamoxifen-treated and vehicle 
control transplant Mdm2Tg p53Neo/Neo CreER angiosarcomas.  
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Suppression of Cell Proliferation Upon p53 Restoration 
 
As aforementioned, activation of p53 can exert different biological functions 
including cell cycle arrest, senescence and apoptosis. To examine the biological 
and cellular effects of p53 restoration in the Mdm2Tg p53Neo/Neo CreER 
angiosarcomas, I analyzed the proliferation index by immunohistochemistry in 
tumors with chronic (4 doses) tamoxifen treatment. Upon tamoxifen treatment, an 
average of 48% of cells were positive for proliferation marker Ki-67 in Mdm2Tg 
p53Neo/Neo angiosarcomas, while approximately only 20% of cells were positively 
stained with Ki-67 antibody in the Mdm2Tg p53Neo/Neo CreER angiosarcomas 
(Figure 25a, 25c, and 25d), indicating that chronic tamoxifen treatment-mediated 
p53 restoration leads to cell cycle arrest in Mdm2-overexpressing angiosarcomas. 
I also analyzed Ki-67 positivity in the Mdm2Tg p53Neo/Neo CreER angiosarcomas at 
3 days after 1 dose of tamoxifen treatment to examine the acute effects of p53 
restoration. The percentage of Ki-67 positive cells between Mdm2Tg p53Neo/Neo 
CreER angiosarcomas undergoing chronic and acute tamoxifen treatment was 
comparable to each other (Figure 25b, 25c and 25d), suggesting that p53 
restoration may result in sustained cell cycle arrest in Mdm2-overexpressing 
angiosarcomas.  
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Figure 25. p53 restoration resulted in reduced cell proliferation in Mdm2Tg 
p53Neo/Neo CreER angiosarcomas. Tamoxifen-treated Mdm2Tg p53Neo/Neo and 
Mdm2Tg p53Neo/Neo CreER angiosarcomas were subjected to 
immunohistochemical staining for proliferation marker Ki-67. a), b) and c) Images 
of the representative angiosarcomas from the tamoxifen-treated Mdm2Tg 
p53Neo/Neo mice, and Mdm2Tg p53Neo/Neo CreER mice with 1 dose or  4 doses of 
tamoxifen treatment, respectively. d) Percentages of cells positive for Ki-67 in 
tamoxifen-treated Mdm2Tg p53Neo/Neo and Mdm2Tg p53Neo/Neo CreER 
angiosarcomas. Four random fields (Χ40 magnification) for each tumor were 
chosen to calculate the percentages. Differences in the percentages of Ki-67 
positive cells between genotypes were analyzed with 2-tailed Student’s t test. 
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I also analyzed the expression of cellular senescence in the tamoxifen-
treated spontaneous angiosarcomas. In Mdm2Tg p53Neo/Neo CreER 
angiosarcomas, 3 out of 9 tumors treated with 4 doses of tamoxifen and 4 out of 
5 treated with 1 dose of tamoxifen were positive for IHC staining of senescence 
marker PML; and no positive PML staining were observed in any tamoxifen-
treated Mdm2Tg p53Neo/Neo angiosarcomas (n=6) (Figure 26). Although no 
statistically significant difference (p=0.11, Chi-square analysis) was observed for 
the PML staining between tamoxifen-treated Mdm2Tg p53Neo/Neo angiosarcomas 
and Mdm2Tg p53Neo/Neo CreER angiosarcomas with 4 doses of tamoxifen, the 
PML staining of Mdm2Tg p53Neo/Neo CreER angiosarcomas with 1 dose of 
tamoxifen was very significantly different from that of tamoxifen-treated Mdm2Tg 
p53Neo/Neo angiosarcomas (p<0.01, Chi-square analysis). Therefore, the data 
here suggest that restoration of functional p53 expression induces a senescence 
response at least in a proportion of the Mdm2-overexpressing angiosarcomas. 
In order to analyze the apoptotic effects of p53 restoration in the Mdm2Tg 
p53Neo/Neo CreER tumors, I compared the levels of cleaved caspase 3, an 
apoptotsis marker, by immunohistochemistry between the tamoxifen-treated 
Mdm2Tg p53Neo/Neo CreER and Mdm2Tg p53Neo/Neo angiosarcomas. Interestingly, 
no apoptosis was induced in the Mdm2Tg p53Neo/Neo CreER angiosarcomas with 
either chronic or acute tamoxifen treatment compared to Mdm2Tg p53Neo/Neo 
angiosarcomas (Figure 27), indicating that reintroduction of p53 in these tumors 
does not induce an apoptotic response mediated by cleaved caspase 3. 
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In summary, p53 restoration in Mdm2Tg p53Neo/Neo angiosarcomas only 
induced suppression of cell proliferation and senescence but not apoptosis, 
which is consistent with observations reported by previous studies that p53 
restoration in angiosarcomas lacking p53 did not result in an apoptotic phenotype 
(Ventura et al., 2007; Wang et al., 2011). These data collectively suggest that 
intrinsic characteristics of angiosarcomas dictate their responses to p53 
restoration. 
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Figure 26. p53 restoration resulted in induction of senescence in Mdm2Tg 
p53Neo/Neo CreER angiosarcomas. Tamoxifen-treated Mdm2Tg p53Neo/Neo and 
Mdm2Tg p53Neo/Neo CreER angiosarcomas were subjected to 
immunohistochemical staining for senescence marker PML. a), b) and c) Images 
of the representative angiosarcomas from the tamoxifen-treated Mdm2Tg 
p53Neo/Neo mice, and Mdm2Tg p53Neo/Neo CreER mice with 1 dose or  4 doses of 
tamoxifen treatment. 
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Figure 27.  p53 restoration did not result in apoptosis in Mdm2Tg p53Neo/Neo 
CreER angiosarcomas. Tamoxifen-treated Mdm2Tg p53Neo/Neo and Mdm2Tg 
p53Neo/Neo CreER angiosarcomas were subjected to immunohistochemical 
staining for apoptosis marker cleaved caspase 3. a), b) and c) Images of the 
representative angiosarcomas from the tamoxifen-treated Mdm2Tg p53Neo/Neo 
mice, and Mdm2Tg p53Neo/Neo CreER mice with 1 dose or  4 doses of tamoxifen 
treatment. d) Image of an IR-treated mouse spleen as a positive control. CC3, 
cleaved caspase 3.   
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CHAPTER 3. DISCUSSION 
 
Mdm2 negatively regulates p53 functions by suppressing its transcription 
activity and targeting it for degradation. Thus, it is reasonable to postulate that 
restoring p53 expression in tumors with high levels of Mdm2 may not render 
therapeutic effectiveness. However, patients with tumors featuring both Mdm2 
overexpression and p53 mutation have more malignant diseases and poorer 
prognosis than patients with tumors carrying either alteration alone. In addition, 
Mdm2Tg mice in p53−/− background develop tumors significantly earlier than 
Mdm2Tg mice with wild-type p53. These data suggest an additive effect of Mdm2 
overexpression with loss of p53. Therefore, p53 restoration in Mdm2-
overexpressing tumors may lead to alleviated diseases. To test whether p53 
restoration in Mdm2-overexpressing tumors would have therapeutic efficacy, we 
established a mouse model with high levels of Mdm2 and decreased p53. Upon 
restoring wild-type p53 expression, Mdm2-overexpressing angiosarcomas 
underwent growth suppression and regression, suggesting that increasing p53 
expression levels can render therapeutic benefits to tumors with high levels of 
Mdm2. This finding provides in vivo experimental evidence for treating Mdm2-
overexpressing tumors by p53 gene delivery. 
 
p53 Reactivation in Mdm2-overexpressing Tumors 
Growth suppression was observed in Mdm2Tg p53Neo/Neo CreER 
angiosarcomas after p53 restoration, similar to the effects of p53 restoration in 
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previous studies, which showed that p53 restoration in p53-deficient tumors 
results in tumor suppression (Wang et al., 2011; Xue et al., 2007). However, the 
findings from the present study are also distinct from previous reports. Both 
tumor stasis and regression were observed when two copies of wild-type p53 
were restored in Mdm2Tg p53Neo/Neo CreER angiosarcomas, whereas restoration 
of a single copy of wild-type p53 led to regression in all angiosarcomas not 
carrying the Mdm2 transgene (Wang et al., 2011). Such attenuated response to 
p53 restoration in the present study may be ascribed to the higher levels of 
Mdm2 in Mdm2Tg p53Neo/Neo CreER angiosarcomas. 
Our present study indicates that elevating p53 expression levels confers 
tumor suppression in Mdm2-overexpressing angiosarcomas, it is therefore of 
interest to ask why high levels of Mdm2 in these tumors does not totally mask the 
activities of restored p53 in these tumors. Previous studies have shown that 
components of Myc and Ras oncogenic pathways are overexpressed in majority 
of angiosarcoma cases (Fernandez-Medarde and Santos, 2011; Guo et al., 2011; 
Kurisetty and Bryan, 2013; Przygodzki et al., 1997; Shon et al., 2013; Zietz et al., 
1998). Sustained activation of such oncogene pathways is indispensable for 
tumor progression (Weinstein, 2002), since blocking the signaling of these 
oncogenic pathways shows tumor-suppressive effects (Downward, 2003; 
LaMontagne et al., 2000; Singh et al., 2009; Soucek et al., 2008; Soucek et al., 
2013). Activation of the Ras and Myc oncogenic pathways results in upregulation 
of tumor suppressor Arf that binds Mdm2 and releases p53 from its talons 
(Ozenne et al., 2010), and subsequently leads to accumulation and activation of 
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p53 (Dai et al., 2006; Ozenne et al., 2010). Interestingly, activation of Myc and 
Ras oncogenic pathways in cells also cause genomic instability by elevated 
production of reactive oxygen species (ROS) and suppression of DNA damage 
repair (Felsher and Bishop, 1999; Fest et al., 2002; Li et al., 2012; Saavedra et 
al., 1999; Saavedra et al., 2000; Soucek and Evan, 2002; Wade and Wahl, 2006). 
DNA damage sensor kinases such as ATM and ATR in response to such 
genomic stresses catalyze phosphorylation of p53, which disrupts Mdm2-p53 
interaction and thus activates p53. Hence, in our Mdm2-overexpressing 
angiosarcomas, it is likely that constitutive activation of oncogenic pathways by 
overexpression of Myc and Ras pathway components results in activation of 
restored p53 in the presence of high levels of Mdm2. This notion is in agreement 
with our data in MEFs, which clearly showed that ectopically expressing 
oncogene H-RasG12V led to accumulation of p53 and potentiated p53 
transcriptional activity upon restoration even in an Mdm2-overexpressing setting.   
It is well documented that tumors in general impose selective pressure on 
the p53 pathway in order to maintain aberrant growth (Sherr, 1998). And yet, in 
the present study, reactivated p53 induces expression of downstream target 
genes such as p21 and Puma, and therefore leads to growth suppression of 
tumors, suggesting that the p53 pathway remains intact except for the introduced 
alterations on p53 and Mdm2. One plausible explanation for such an observation 
is that due to the excessive amount of Mdm2 and the extremely low level of p53 
in Mdm2Tg p53Neo/Neo CreER angiosarcomas, it is unlikely that selection pressure 
is imposed on the p53 pathway, and thus other components of the p53 pathway 
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remain intact in these tumors, which warrant the therapeutic efficacy of p53 
restoration. However, further investigation is needed to understand the 
mechanisms of activating restored p53 in the Mdm2-overexpressing 
angiosarcomas, which may lead to better therapies of tumors with high levels of 
Mdm2. 
 
Effects of p53 Gene Dosage 
In the present study, I have showed that Mdm2Tg p53Neo/Neo mice have 
dampened levels and activities of p53 compared to Mdm2Tg or p53Neo/Neo mice, 
which leads to earlier tumor onset in the Mdm2Tg p53Neo/Neo mice. This 
observation is consistent with earlier studies showing that p53−/− mice develop 
tumor significantly earlier than p53+/− mice (Donehower et al., 1992; Jacks et al., 
1994). These data collectively indicate p53 exerts tumor-suppressive functions in 
a dose-dependent manner.  
As to the dose-dependent function of p53 in Mdm2-overexpressing tumors, 
clear discrepancy exists in clinical data. The fact that majority of Mdm2-
overexpressing tumors lack p53 mutations (Momand et al., 1998; Oliner et al., 
1992) leads to the speculation that Mdm2 overexpression and loss of wild-type 
p53 are mutually exclusive events during tumor development. But the 
observation that concomitant existence of Mdm2 overexpression and p53 
mutations in human cancers results in more malignant diseases and poorer 
prognosis than either alteration alone (Gorgoulis et al., 2000; Gorgoulis et al., 
1996; Li et al., 2000; Marks et al., 1996) suggests that loss of p53 provides 
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additional growth advantage to tumor cells even in the present of high levels of 
Mdm2. However, there was no direct evidence for dose-dependent tumor-
suppressive activity of p53 in Mdm2-overexpressing tumors. In the present study, 
the observation that Mdm2Tg p53Neo/Neo mice have earlier tumor onset than 
Mdm2Tg mice also suggests that loss of p53 confers growth advantage even in 
the presence of high levels of Mdm2, providing support for dose-dependent 
effects of p53 in Mdm2-overexpressing settings.  
In a previous study, Mdm2Tg/Tg mice had significantly shortened tumor-free 
survival compared to Mdm2Tg/+ mice (Jones et al., 1998). In Eu-myc transgenic 
mice, deletion of one copy of Mdm2 results in augmented p53 activities and thus 
delays onset of lymphomas driven by the Eu-myc transgene compared to 
transgenics with intact Mdm2 alleles (Alt et al., 2003). These observations 
together suggest that the Mdm2:p53 ratio is critical for tumorigenesis. In the 
present study, p53 restoration in Mdm2Tg p53Neo/Neo CreER angiosarcomas leads 
to tumor growth suppression implies that the Mdm2:p53 ratio may also be 
important for the maintenance of established tumors.  
 
Clinical Implications 
Pharmaceutically restoring p53 function in Mdm2-overexpressing tumors 
includes identifying Mdm2 inhibitors. However, the nature of Mdm2 inhibitors 
determines the limitations of these pharmaceuticals in tumor treatments. Since 
the therapeutic efficacy of Mdm2 inhibitors is dependent on the presence of wild-
type p53 in the tumors (Li and Lozano, 2013), treatments with the Mdm2 
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inhibitors are unlikely to induce anti-tumor effects in tumors with concurrent 
Mdm2 overexpression and p53 loss. Moreover, a number of studies have 
revealed that administration of Mdm2 inhibitors including nutlin-3 and Mi-219 to 
tumor cells with wild-type p53 potently selects for p53 mutations and thus confers 
resistance to such drugs (Aziz et al., 2011; Jones et al., 2012; Long et al., 2010; 
Michaelis et al., 2011). Hence, alternative approaches, e.g. p53 gene delivery, 
which overcomes such limitations of Mdm2 inhibitors, may benefit patients 
carrying tumors with high levels of Mdm2. Previous studies have demonstrated 
that ectopically expressing wild-type p53 via gene transfer confers anti-tumor 
effects in both pre-clinical and clinical studies (Cai et al., 1993; Fujiwara et al., 
1994; Roth et al., 1996). However, there is no information available for p53 gene 
delivery in Mdm2-overexpressing tumors in human. It is natural to speculate that 
this approach may not be effective for treatment of Mdm2-overexpressing tumors, 
since high levels of Mdm2 can readily degrade p53 and suppress its 
transcriptional activity. Using a genetically engineered mice to model p53 
restoration in Mdm2-overexpressing tumors, our present study indicates that 
restoring expression of p53 in tumors with high levels of Mdm2 is able to 
suppress tumor growth.  
However, it should be noted that our present model does not accurately 
mimic high levels of Mdm2 in human cancers. Many human tumors that retain 
wild-type p53 have 10-50 fold increase in Mdm2 levels (Alazzouzi et al., 2007; 
Forslund et al., 2008; Onel and Cordon-Cardo, 2004), which cannot be achieved 
in the Mdm2Tg mouse model due to embryonic lethality caused by very high 
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levels of Mdm2 (Jones et al., 1998). And yet, our Mdm2Tg p53Neo/Neo mouse tumor 
model with ~4-fold increase in Mdm2 levels and ~5-fold decrease in p53 levels 
better mimics the Mdm2:p53 ratio in human Mdm2-overexpressing tumors with 
20-fold increase in Mdm2 levels and wild-type p53. As to Mdm2:p53 ratio, p53 
restoration in our Mdm2-overexpressing mouse tumors is similar to 
overexpression of p53 by 5 folds in human tumors with high levels of Mdm2. 
Therefore, growth suppression of Mdm2-overepressing tumors by p53 restoration 
manifested in our current study suggests potential effectiveness of p53 gene 
therapy of human tumors featuring high Mdm2 levels.  
A study recently published by our group demonstrated that treatment of 
mouse MMTV-Wnt1 mammary tumors with the DNA-damaging drug doxorubicin 
resulted in inferior antitumor responses such as less extent of regression and 
earlier relapse in tumors with wild-type p53 compared to tumors with mutant p53 
(Jackson et al., 2012). Upon doxorubicin treatment, mammary tumor cells with 
mutant p53 failed to arrest, divided with extensive DNA damage, and underwent 
mitotic catastrophe, while tumor cells with wild-type p53 circumvented apoptosis 
via p53-mediated proliferative arrest (Jackson et al., 2012). Such wild-type p53-
associated inferior responses to chemotherapies were also observed in other 
preclinical and clinical studies (Kim et al., 2009; Wong et al., 2013). These 
observations together suggest that the presence of wild-type p53 in tumors may 
undermine the effectiveness of therapeutic regimens at least in particular 
conidtions. Therefore, it is of important clinical relevance to ask whether p53 
reactivation will cooperate with or antagonize conventional DNA damage p53-
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activating chemotherapies and radiotherapy in tumor treatment. Intriguingly, 
combining p53 restoration with IR treatment in Eu-myc lymphomas prolongs the 
survival of tumor-carrying mice compared to treatment of either regimen alone 
(Martins et al., 2006). Reactivation of p53 by inhibitors of Mdm2 and Mdm4 also 
cooperates with DNA-damaging pharmaceuticals to induce growth inhibition and 
apoptosis in various human cell lines of different tumor types including breast 
cancer, pancreatic cancer, colon cancer, liver cancer, neuroblastoma, 
retinoblastoma, and sarcomas (Azmi et al., 2011; Barbieri et al., 2006; Costa et 
al., 2013; Ohnstad et al., 2011; Zheng et al., 2010). These data collectively 
suggest p53 reactivation can sensitize tumors to treatments with DNA-damaging 
agents. Since it is out of our current focus, DNA-damaging drug treatment 
combined with p53 restoration to Mdm2-overexpressing tumors was not 
performed in the present study. And yet, our in vitro indicate that p53 restoration 
cooperates with doxorubicin treatment in induction of p53 target genes in Mdm2-
overexpressing MEFs, suggesting that p53 restoration potentiates p53 activity 
induced by DNA damaging drugs in an Mdm2-overexpressing background. 
Future studies with such combinatorial treatments may help us to understand 
whether and how restored wild-type p53 affect tumor responses to DNA-
damaging agents in Mdm2-overexpressing tumors.  
 
Future Directions 
Identification of cellular determinant(s) of p53-induced apoptosis and cell cycle 
arrest 
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Although p53 exerts its growth-suppressive activities by inducing apoptosis, 
cell cycle arrest and senescence programs (Jackson et al., 2011), different 
tissues respond differently to a variety of stimuli due to understudied 
mechanisms (Jackson et al., 2011). In an early study, p53 expression in 
colorectal cancer cell lines yielded arrest phenotypes in some lines and apoptotic 
response in others (Polyak et al., 1996). Interestingly, deletion of p21 (an effector 
of p53-mediated cell cycle arrest) in arrested cell lines led to p53-induced 
apoptosis (Polyak et al., 1996). Moreover, hybrid cells resulted from fusing an 
arrested line to an apoptotic line underwent apoptosis upon p53 expression 
(Polyak et al., 1996). In a recent report, a transcription factor AATF (apoptosis-
antagonizing transcription factor) bound to the promoters of Puma, Bax and Bak, 
repressed the p53-induced expression of these apoptotic genes, and therefore 
inhibited p53-mediated apoptotic response (Hopker et al., 2012). These 
observations together indicate that specific factors exist in cells, which dictate 
cellular responses to p53 activation.  
In the present study, cell cycle arrest but no apoptosis has been observed in 
the angiosarcoms after p53 restoration. This observation is consistent with 
previous studies showing that restoration of p53 in sarcomas, including 
angiosarcomas, results in cell cycle arrest but no apoptosis (Ventura et al., 2007; 
Wang et al., 2011). These data suggest that cell cycle arrest is determined as the 
default program induced by p53 restoration in angiosarcomas. It is therefore of 
interest to ask what factors dictate such an arrest response to p53 restoration in 
angiosarcomas. To this end, I propose to identify such factors via a genome-wide 
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shRNA screening strategy. Briefly, a barcoded lentiviral shRNA library will be 
used to transduce Mdm2Tg p53Neo/Neo CreER angiosarcoma cell lines established 
in the present study. Then, I will restore p53 expression by 4-hydroxytamoxifen 
treatment in pooled cells with stable shRNA expression. Subsequently, barcode 
sequencing will be performed to identify shRNAs which are underrepresented in 
the 4-hydroxytamoxifen-treated cells in comparison to that of control cells. 
Theoretically, genes repressed by such shRNAs may function to reinforce p53-
mediated cell cycle arrest/senescence and/or repress p53-induced apoptosis. I 
will then perform functional studies, e.g. overexpression of identified factors in a 
set of selected cell lines to confirm their roles in determining p53-induced 
responses. Identification of such cellular determinants of p53-induced response 
will not only further our knowledge of the p53 pathway, but also provide 
therapeutic targets for treatment of tumors resistant to p53-induced apoptosis. 
 
Paracrine Effects of Tumor Cells 
 One of the interesting findings from the present study is that the growth of 
Mdm2Tg p53Neo/Neo CreER angiosarcomas was completely stopped and some 
tumors even underwent regression upon p53 restoration; however, only 30-40% 
recombination was observed in the tamoxifen-treated Mdm2Tg p53Neo/Neo CreER 
angiosarcomas, indicating that a large proportion of tumor cells did not have 
restored p53 expression. This inconsistency between p53 restoration and tumor 
response suggests that tumor cells without p53 restoration may sense the 
change from p53-restored cells. It has been reported that p53 induces Mdm2-
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mediated HIF-1α (hypoxia-inducible factor 1-alpha) degradation and suppresses 
HIF-1α induced VEGF (vascular endothelial growth factor) expression (Ravi et al., 
2000). In addition, expression of VEGF promotes proliferation of angiosarcoma 
cells in autocrine and paracrine manners (Tokuyama et al., 2010). These data 
suggest that p53 expression in angiosarcoma tumor cells may affect neighboring 
cells via secretory factors. Therefore, I hypothesize that p53 restoration in the 
Mdm2Tg p53Neo/Neo CreER cells leads to altered secretory profiles, which affect 
the growth of neighboring cells. To test this hypothesis, RNA-seq analyses can 
be performed to identify differences in expression profiles especially for secretory 
factors between tamoxifen-treated Mdm2Tg p53Neo/Neo and Mdm2Tg p53Neo/Neo 
CreER angiosarcomas. In particular, upon tamoxifen treatment secretory factors 
upregulated in Mdm2Tg p53Neo/Neo CreER angiosarcomas may contribute to 
growth inhibition of tumors, whereas secretory factors downregulated may 
promote tumor growth. Subsequently, the functions of such factors in inhibiting 
tumor growth will be tested in both in vitro and in vivo systems. Identification of 
such factors may advance our understanding of cell-cell communication in 
tumors, and help to develop better therapeutic approaches. 
 
In summary, mouse models such as the present study have shed light on 
tumor development in the context of the whole-body system, intact immune 
system, and unstressed conditions. In addition, modeling tumor responses to 
alterations in specific genes in genetically modified mice provide unique tools to 
identify druggable candidates for targeted cancer therapies in human patients. 
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Hopefully, the invaluable findings generated from these studies will be translated 
to clinic and benefit cancer patients. 
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CHAPTER 4. MATERIALS AND METHODS 
 
Mice 
The p53Neo/Neo mice (Wang et al., 2011) were crossed with Mdm2Tg mice (Jones 
et al., 1998) to generate Mdm2Tg p53Neo/+ mice. The Mdm2Tg p53Neo/+ mice were 
backcrossed with p53Neo/Neo mice to generate Mdm2Tg p53Neo/Neo mice. The 
p53Neo/Neo mice were crossed with CreER transgenic mice to generate p53Neo/+ 
CreER mice, and the p53Neo/+ CreER mice were backcrossed with p53Neo/Neo mice 
to generate p53Neo/Neo CreER mice. Mdm2Tg p53Neo/Neo mice were crossed with 
p53Neo/Neo CreER mice to generate Mdm2Tg p53Neo/Neo and Mdm2Tg p53Neo/Neo 
CreER mice. All Mdm2Tg, p53Neo/Neo, Mdm2Tg p53Neo/Neo, and Mdm2Tg p53Neo/Neo 
CreER mice were maintained in a genetic background of over 95% C57BL/6J. 
The mice were bred and maintained in the mouse facility at the University of 
Texas M.D. Anderson Cancer Center in compliance with the Institutional Animal 
Care and Use Committee guidelines.  
 
Magnetic Resonance Imaging (MRI) 
All MRI studies were performed in the Small Animal Imaging Facility at the 
University of Texas M.D. Anderson Cancer Center. Mice were subjected to 
anesthesia during the MRI. Five percent isoflurane in oxygen was used to initiate 
anesthesia and then 2-3% isoflurane in oxygen was used to maintain anesthesia 
during MRI. Respiratory bellows in conjunction with a monitoring and gating 
system (Small Animal Instruments, Inc) were used to monitor physiological 
conditions of anesthetized mice. The magnetic resonance (MR) images were 
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acquired using a 7 Tesla small animal MR system BioSpec USR70/30 (Bruker 
Biospin MRI) with a 6-cm imaging gradient. A RF coil with 3.5-cm internal 
diameter was used for signal excitation and detection. The MRI procedure was 
conducted as previously described (Wang et al., 2011). T2-weighted coronal and 
axial MR image stacks were used to calculate tumor volumes using ParaVision 
4.0 software (Bruker Biospin MRI). 
 
Tamoxifen Treatment 
Tamoxifen (Sigma-Aldrich) was prepared as a 30 mg/mL stock solution with corn 
oil:ethanol mixture (95.5:4.5, v/v). Tumor-carrying mice received weekly 
intraperitoneal (i.p.) injectionof tamoxifen at a dose of 3 mg/40 g bodyweight. 
Tamoxifen treated mice were closely monitored for up to 4 weeks or till morbidity 
and then sacrificed. 
 
Transplantation 
The primary Mdm2Tg p53Neo/neo CreER angiosarcoma was excised from a 
euthanized mouse, extensively diced with a scalpel blade, and trypsinized at 37 
°C for 10 minutes. Dulbecco's modified Eagle's medium (DMEM) with 10% fetal 
bovine serum was used to inactivate trypsin and then the mixture was passed 
through a 40 µM filter to remove cell debris. Tumor cells were resuspended in 
PBS:Matrigel mixture (2:1, v/v) to a final density of 2 ×107/mL at 4 °C, following 
PBS washing. Two million tumor cells in PBS:Matrigel solution (100 µL) were 
injected subcutaneously into the flanks of C57BL/6J mice. Tumor formation was 
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monitored by palpation. The sizes of these tumors were monitored with digital 
calipers and tumor volumes were calculated using the equation 
[(width2×Length)/2] as described previously (Bearss et al., 2000). 
 
Histopathology and Immunohistochemistry 
Mouse tissues were processed for histopathological analysis as previously 
described (Lang et al., 2004).  Briefly, fresh tissue samples were excised from 
euthanized mice, washed with cold phosphate buffered saline, and then fixed in 
10% formalin for 48 hours. Fixed tissue samples were embedded in paraffin and 
then sectioned into slices with 4 µM thickness. Histological preparation of mouse 
tissue samples and hematoxylin and eosin (H&E) staining were conducted in the 
Department of Veterinary Medicine at the University of Texas M.D. Anderson 
Cancer Center. Immunohistochemical staining was performed on paraffin-
embedded tissue sections as previously described (Evans et al., 2001), using 
antibodies for Ki-67 (MM1, Leica Biosystems; 1:200), cleaved caspase-3 (5A1E, 
Cell Signal Technology; 1:200), and PML (PG-M3, Santa Cruz Biotechnology; 
1:100). Signals were detected using the Vectastain Elite ABC Kit (Vector Labs), 
and counterstaining was performed using Nuclear Fast Red (Vector Labs). 
 
Murine Embryonic Fibroblast (MEF) Preparation, Cell Culture and Methyl 
Thiazolyl Tetrazolium (MTT) Assay  
MEFs were established from 13.5 days post coitum embryos as previously 
described (Terzian et al., 2007). The culture conditions for maintaining MEFs 
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were the same as previously described (Terzian et al., 2007). pBabe-puro based 
retroviral vectors were used to transduce Phoenix-eco cells to produce retroviral 
particles; and then retroviral particles collected from the Phoenix-eco cell medium 
were used to infect MEFs. MEFs infected with these retroviral particles were 
subjected to screening for puromycin-resistance in culture medium with 2 µg/mL 
puromycin for 4 days. 4-hydroxytamoxifen treatment to MEFs was performed 
using culture medium containing 1 µM 4-hydroxytamoxifen. In order to elicit DNA-
induced p53 activation in MEFs, cells were incubated in culture medium with 1 
µg/mL doxorubicin for 4 hours. For MTT assays, cells were incubated in culture 
medium with 125 µg/ml MTT for 3 hours followed by DMSO incubation for 20 
minutes, and the optical absorbance was measured at the wavelength of 550 nm. 
 
Real-time Reverse Transcription-PCR (qRT-PCR) 
Total RNAs were isolated from MEFs or mouse tissues using TRIzol reagent 
(Life Technologies) following manufacturer’s instructions. Reverse transcription 
reactions for first-strand cDNA synthesis were performed using the First-Strand 
cDNA Synthesis Kit with random hexamers as primers (GE Healthcare). Real-
time PCR was performed on a 7900HT Fast Real-time PCR system (Applied 
Biosystems) using iTaq SYBR Green Supermix with ROX or SsoAdvanced 
SYBR Green Supermix (Bio-Rad). Primer sets used in the real-time PCR probing 
for p21, Mdm2, Puma, Noxa, and Rplp0 are listed below: p21, 5’-
CAGGCACCATGTCCAATCCT -3’ and 5’-GAGACAACGGCACACTTTGCT-3’; 
Mdm2, 5’-AGTCCCATGAAGAGATTGTACATGAC-3’ and 5’-AACATAGGCAACC 
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ACCAGGAA-3’; Puma, 5’-GCGGCGGAGACAAGAAGA-3’ and 5’-AGTCCCATG 
AAGAGATTGTACATGAC-3’; Rplp0, 5’-CCCTGAAGTGCTCGACATCA-3’ and 
5’-TGCGGACACCCTCCAGAA-3’. In all qRT-PCR experiments, mRNA 
expression was normalized to the Rplp0 levels. 
 
Western blotting 
Proteins were extracted from MEFs or homogenized mouse tissues using 
radioimmunoprecipitation assay (RIPA) buffer with cOmplete proteinase 
inhibitors (Roche Applied Science). Proteins, resolved in SDS-PAGE and 
transferred to PVDF membranes, were incubated with antibodies against p53 
(CM5, Vector Laboratories; 1:1000), Mdm2 (2A10, Calbiochem; 1:1000), p21 (F-
5, Santa Cruz Biotechnology; 1:1000), H-Ras (sc-35, Santa Cruz Biotechnology; 
1:200), β-actin (AC-74, Sigma-Aldrich; 1:5000), and γ-tubulin (Sigma-Aldrich; 
1:1000), respectively. Membrane-bound proteins were then visualized with ECL 
Western blotting detection reagent (GE Healthcare), following incubation with 
appropriate horseradish peroxidase-conjugated secondary antibodies (GE 
Healthcare). 
 
Statistics 
All statistical analyses were performed using the Graphpad Prism 5.0 software 
(Graphpad Software). Differences between genotypes or treatment groups were 
analyzed with 2-tailed Student’s t test; and difference between survival curves 
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was determined via Log-rank (Mantel-Cox) Test. A p value of ≤0.05 was deemed 
statistically significant. 
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